Tapi[INVESTIGATOR_222143].: DMVT -505-3101, Amendment [ADDRESS_266946] or Independent Ethics Committee.  The information is only to be used by [CONTACT_222184].  You will not di sclose any of the 
information to others without written authorization from Dermavant Sciences , Inc. except to the extent necessary to obtain informed 
consent from those persons to whom the drug may be administered.  
Confidential  Page | 1 Clinical Study Protocol  
Study Title:  A Phase 3 Efficacy and Safety Study of Tapi[INVESTIGATOR_222144]:  Dermavant Sciences, Inc.  
[ADDRESS_266947]  
Morrisville, NC, [LOCATION_003]  [ZIP_CODE]  
Compound Name:  [CONTACT_66597][INVESTIGATOR_222145]:  DMVT -505-3101  
Indication:  Atopic Dermatitis  
Development Phase:  3 
IND Number:  104601  
Current Version:  4.0 
Approved/Effective Date:  Version 1.0, Approved: 24 M ar 2021  
Version 2.0, Amendment 1 Approved:16 J un 2021  
Version 3.0, Amendment 2 Approved:  12 Aug 2021  
Version 4.0, Amendment 3 Approved : 09 Aug 2022  

Tapi[INVESTIGATOR_222143].: DMVT -505-3101 , Amendment 3 
Dermavant Sciences , Inc.  Clinical Study Protocol  
Confidential  Page | 2  
 
Sponsor Signature [CONTACT_222226]:  A Phase 3 Efficacy and Safety Study of Tapi[INVESTIGATOR_222146]:  DMVT -505-3101  
Current Version:  Version  4.0, Amendment 3 Approved: 09 Aug 2022  
  
  
This protocol has been approved by a representative of Dermavant Sciences, Inc.  The following signature 
[CONTACT_139142].  
 
 
 
 
 
 

Tapi[INVESTIGATOR_222143].: DMVT -505-3101 , Amendment 3 
Dermavant Sciences , Inc.  Clinical Study Protocol  
Confidential  Page | 3  
Medical Monitor / Sponsor Information Page  
 
 
 

Tapi[INVESTIGATOR_222143].: DMVT -505-3101 , Amendment 3 
Dermavant Sciences , Inc.  Clinical Study Protocol  
Confidential  Page | 4  
Investigator Statement  
 
 
Study Title:  A Phase 3 Efficacy and Safety Study of Tapi[INVESTIGATOR_222146]:  DMVT -505-3101  
Current Version:  Version 4, Amendment 3Approve d: 09 Aug 2022  
 
• I confirm agreement to conduct the study in compliance with the protocol.  
• I acknowledge that I am responsible for overall study conduct.  I agree to personally conduct or 
supervise the described study.  
• I agree to ensure that all associates, colleagues, and employees assisting in the conduct of the study 
are informed about their obligations and comply with the study protocol.  Mechanisms are in place 
to ensure that site staff receives the appropriate information throughout the study.  
 
 
 
 
 
 
 
 
 

Tapi[INVESTIGATOR_222143].: DMVT -505-3101 , Amendment 3 
Dermavant Sciences , Inc.  Clinical Study Protocol  
Confidential  Page | 5 Table of Contents   
Synopsis     .  ................................ ................................ ................................ ................................ .....................  13 
1 Introduction  ................................ ................................ ................................ ................................ ... 23 
1.1 Background Information and Study Rationale  ................................ ................................ .............  23 
1.1.1  Background Information  ................................ ................................ ................................ ...............  23 
1.1.2  Study Rationale  ................................ ................................ ................................ .............................  24 
1.2 Rationale for Study Design, Dose, and Control Groups  ................................ ...............................  24 
1.3 Potential Risks and Benefits  ................................ ................................ ................................ .........  26 
  
  
  
  
1.3.2  Benefit Assessment  ................................ ................................ ................................ .......................  28 
1.3.3  Overall Benefit Risk  ................................ ................................ ................................ .....................  28 
2 Objectives and Endpoints  ................................ ................................ ................................ .............  29 
3 Study Design  ................................ ................................ ................................ ................................ . 31 
3.1 Overall Design  ................................ ................................ ................................ ..............................  31 
3.2 Treatment Groups and Duration  ................................ ................................ ................................ ... 32 
3.3 Definition of Study Completion and Eligibility for Open -Label, Long -Term Extension 
Study  ................................ ................................ ................................ ................................ .............  32 
4 Study Population  ................................ ................................ ................................ ...........................  33 
4.1 Type and Number of Subjects  ................................ ................................ ................................ ...... 33 
4.2 Inclusion Criteria  ................................ ................................ ................................ ..........................  33 
4.3 Exclusion Criteria  ................................ ................................ ................................ .........................  34 
4.4 Lifestyle Restrictions  ................................ ................................ ................................ ....................  36 
4.5 Screening/Baseline Failures ................................ ................................ ................................ ..........  [ADDRESS_266948] to Follow -Up................................ ................................ ................................ .........................  38 
5 Study Treatment  ................................ ................................ ................................ ............................  39 
5.1 Study Drug  ................................ ................................ ................................ ................................ .... 39 
5.1.1  Descript ion, Packaging, and Labeling  ................................ ................................ ..........................  39 
5.1.2  Storage  ................................ ................................ ................................ ................................ ..........  39 
5.1.3  Handling and Disposal  ................................ ................................ ................................ ..................  39 

Tapi[INVESTIGATOR_222143].: DMVT -505-3101 , Amendment 3 
Dermavant Sciences , Inc.  Clinical Study Protocol  
Confidential  Page | 6 5.1.4  Preparation  ................................ ................................ ................................ ................................ .... 39 
5.1.5  Administration of Study Drug  ................................ ................................ ................................ ...... 39 
5.1.6   ................................ ................................ ..................  40 
5.2 Randomization/Treatment Assignment  ................................ ................................ ........................  41 
5.3 Blinding  ................................ ................................ ................................ ................................ ........  41 
5.4 Compliance with Study Drug Administration  ................................ ................................ ..............  42 
5.5 Treatment after the End of the Study  ................................ ................................ ............................  42 
5.6 Prior and Concomitant Therapy  ................................ ................................ ................................ .... 43 
5.6.1  Permitted Medications and Nondrug Therapi[INVESTIGATOR_014]  ................................ ................................ ...........  43 
5.6.2  Prohibited Medications and Nondrug Therapi[INVESTIGATOR_014]  ................................ ................................ ..........  43 
6 Study Assessments and Procedures  ................................ ................................ ..............................  44 
6.1 Demography, Medical History, and Baseline Characteristics  ................................ ......................  44 
6.1.1  Demographics  ................................ ................................ ................................ ...............................  44 
6.1.2  Medical History  ................................ ................................ ................................ ............................  44 
6.2 Efficacy Assessments  ................................ ................................ ................................ ...................  44 
6.2.1  Assessments Completed by [CONTACT_10670]  ................................ ................................ ......................  44 
[IP_ADDRESS]  Validated Investigator Global Assessment of Atopic Dermatitis  ................................ .................  44 
[IP_ADDRESS]  Body Surface Area Affected  ................................ ................................ ................................ .........  45 
[IP_ADDRESS]  Eczema Area and Severity Index  ................................ ................................ ................................ .. [ADDRESS_266949] or Caregiver  ................................ ................................ ........  45 
  
 
  
[IP_ADDRESS]  Peak Pruritus -Numeric Rating Scale  ................................ ................................ ............................  46 
  
  
6.2.3  Optional Clinical Photography  ................................ ................................ ................................ ..... 47 
6.3 Safety Assessments  ................................ ................................ ................................ .......................  47 
6.3.1  Adverse Events  ................................ ................................ ................................ .............................  47 
6.3.2  Brief Physical Examination  ................................ ................................ ................................ ..........  47 
6.3.3  Vital Signs  ................................ ................................ ................................ ................................ .... 48 
6.3.4  Clinical Safety Laboratory Assessments  ................................ ................................ ......................  48 
6.3.5  Electrocardiograms  ................................ ................................ ................................ .......................  49 
6.3.6 Local Tolerability Scale  ................................ ................................ ................................ ................  49 
[IP_ADDRESS]  Investigator -Assessed Local Tolerability Scale  ................................ ................................ ............  49 

Tapi[INVESTIGATOR_222143].: DMVT -505-3101 , Amendment 3 
Dermavant Sciences , Inc.  Clinical Study Protocol 
Confidential  Page | 7 [IP_ADDRESS]  Subject (or Caregiver) -Assessed Local Tolerability Scale  ................................ ...........................  49 
6.4 Treatment of Study Drug Overdose  ................................ ................................ ..............................  49 
6.5 Pharmacokinetics  ................................ ................................ ................................ ..........................  50 
6.6 Virtual Assessments  ................................ ................................ ................................ ......................  50 
7 Timing of Procedures and Assessments  ................................ ................................ .......................  52 
7.1 Visit 1; Screening Period (Day -30 to Day -1) ................................ ................................ .............  52 
7.2 Visit 2; Baseline (Day  1) ................................ ................................ ................................ ..............  53 
7.3 Visit 3; Week  1 (Day  8 ±2 Days)  ................................ ................................ ................................ . 54 
7.4 Visit 4; Week  2 (Day  15 ±2  Days)  ................................ ................................ ...............................  54 
7.5 Visit 5; Week  4 (Day  29 ±2  Days)  ................................ ................................ ...............................  55 
7.6 Visit 6; Week  8 (Day  57 ±2  Days)  ................................ ................................ ...............................  [ADDRESS_266950] at Weeks  3 (Day  22 ±2  Days) and 6 (Day  43 ±2  Days)  ................................ ....... 56 
7.8 Follow -Up Visit 7; Week  9 (Day  64 ±2  Days)  ................................ ................................ .............  [ADDRESS_266951]  ................................ ................................ ...............................  61 
8.2 Classification of Adverse Events  ................................ ................................ ................................ .. 62 
8.2.1  Assigning Severity Rating for Adverse Events  ................................ ................................ ............  62 
[IP_ADDRESS]  Criteria for Determining Adverse Event Severity  ................................ ................................ ........  62 
[IP_ADDRESS]  Toxicity Management Criteria  ................................ ................................ ................................ ...... 62 
[IP_ADDRESS].1  Grade 1  or Grade 2  Adverse Event  ................................ ................................ ...............................  62 
[IP_ADDRESS].2  Grade 3  Adverse Event  ................................ ................................ ................................ .................  62 
[IP_ADDRESS].3  Grade 4  Adverse Event  ................................ ................................ ................................ .................  63 
[IP_ADDRESS].4  Folliculitis  ................................ ................................ ................................ ................................ ..... 63 
8.2.1. 2.5 Other Management Criteria:  ................................ ................................ ................................ .........  63 
8.2.2  Assigning Causal Relationship to Study Drug  ................................ ................................ .............  63 
8.3 Time Period and Frequency for Event Assessment and Follow -Up ................................ .............  64 
8.3.1  Adverse Event Reporting  ................................ ................................ ................................ ..............  64 
8.3.2  Follow -Up of Adverse Events  ................................ ................................ ................................ ...... 64 
8.4 Reporting Procedures  ................................ ................................ ................................ ....................  64 
Tapi[INVESTIGATOR_222143].: DMVT -505-3101 , Amendment 3 
Dermavant Sciences , Inc.  Clinical Study Protocol  
Confidential  Page | 8 8.4.1  Serious Adverse Event Reporting  ................................ ................................ ................................ . 64 
8.4.2  Regulatory Reporting Requirements for Serious Adverse Events  ................................ ...............  65 
8.5 Pregnancy Management and Reporting  ................................ ................................ ........................  65 
9 Data Management  ................................ ................................ ................................ .........................  66 
10 Statistical Considerations and Data Analyses  ................................ ................................ ...............  67 
10.1  General Considerations  ................................ ................................ ................................ .................  67 
10.2  Determination of Sample Size  ................................ ................................ ................................ ...... 67 
10.3  Analysis Populations  ................................ ................................ ................................ ....................  67 
10.3.1 Safety  ................................ ................................ ................................ ................................ ............  67 
10.3.2  Intent -To-Treat  ................................ ................................ ................................ .............................  67 
10.3.3  Per-Protocol  ................................ ................................ ................................ ................................ .. 67 
10.3.4  Pharmacokinetic  ................................ ................................ ................................ ...........................  67 
10.4  Planned Analyses  ................................ ................................ ................................ ..........................  67 
10.4.1  Disposition and Demographics  ................................ ................................ ................................ ..... 68 
10.4.2  Efficacy Analyses  ................................ ................................ ................................ .........................  68 
[IP_ADDRESS] Primary Endpoint Analyses  ................................ ................................ ................................ ..........  68 
[IP_ADDRESS]  Secondary and Exploratory Efficacy Endpoint Analyses  ................................ .............................  [ADDRESS_266952]/Independent Ethics Committee Approval  ................................ ........  72 
11.1.3  Informed Consent/Assent  ................................ ................................ ................................ .............  72 
11.1.4  Confidentiality  ................................ ................................ ................................ ..............................  73 
11.1.5  Study Files and Retention of Records  ................................ ................................ ..........................  73 
11.1.6  Electronic Case Report Forms  ................................ ................................ ................................ ...... 74 
11.1.7  Drug Accountability  ................................ ................................ ................................ .....................  74 
11.1.8  Inspections  ................................ ................................ ................................ ................................ .... 74 
11.1.9  Protocol Compliance  ................................ ................................ ................................ ....................  75 
11.2 Sponsor Responsibilities  ................................ ................................ ................................ ...............  75 
11.2.1  Protocol Modifications  ................................ ................................ ................................ .................  75 

Tapi[INVESTIGATOR_222143].: DMVT -505-3101 , Amendment 3 
Dermavant Sciences , Inc.  Clinical Study Protocol  
Confidential  Page | 10 Table of Tables  
Table 1:  Schedule of Assessments  ................................ ................................ ................................ ..............  20 
Table  2: Tapi[INVESTIGATOR_222147]  ................................ ................................ ................................ ....... 39 
Table  3: Validated Investigator Global Assessment Scale for Atopic Dermatitis  ................................ ...... 45 
Table 4:  Laboratory Tests  ................................ ................................ ................................ ...........................  48 
Table  5: Criteria for Determining the Grade/Severi ty of Adverse Event Terms Not Specified by [CONTACT_222185]  ................................ ................................ ................................  62 
Table 6  Primary Estimand Attributes  ................................ ................................ ................................ ........  68 
Table 7.  Calculation of Percent Body Surface Area Affected  ................................ ................................ .... 81 
Table 8.  Calculation of Eczema Area and Severity Index Score for Ages 8 Years and Above  .................  83 
Table 9.  Calculation of Eczema Area and Severity Index Score for Ages < 8 Years  ................................  84 
 
Table of Figures  
Figure  1: Treatment Success (IGA score) by [CONTACT_222186] 203121  ................................ ........  25 
Figure  2:  Study Schema  ................................ ................................ ................................ ...............................  32 
 
 
Tapi[INVESTIGATOR_222143].: DMVT -505-3101 , Amendment 3 
Dermavant Sciences , Inc.  Clinical Study Protocol  
Confidential  Page | [ADDRESS_266953]  aspartate aminotransferase  
BID twice daily  
BMI  body mass index  
BSA  body surface area  
%BSA  percent of total body surface area  
BUN  blood urea nitrogen  
CBP  child -bearing potential  
   
CFR  Code of Federal Regulations  
CMH  Cochran -Mantel -Haenszel  
CRF  case report form  
CTCAE  Common Terminology Criteria for Adverse Events  
CV cardiovascular  
Dermavant  Dermavant Sciences , Inc.  
   
  
EASI  Eczema Area and Severity Index  
ECG  electrocardiogram  
ET early termination  
FSH Follicle -stimulating hormone  
FU follow -up 
  
HBsAg  hepatitis B surface antigen  
   
ICF informed consent form  
IEC Independent Ethics Committee  
IGA Investigator’s Global Assessment  
  
IRB Institutional Review Board  
ITT Intent -to-Treat  
LOCF  last observation carried forward  
LTS Local Tolerability Scale  
MCH  mean corpuscular hemoglobin  

Tapi[INVESTIGATOR_222143].: DMVT -505-3101 , Amendment 3 
Dermavant Sciences , Inc.  Clinical Study Protocol  
Confidential  Page | 12 Term  Full Description  
MCHC  mean corpuscular hemoglobin  concentration  
MCV   mean corpuscular volume  
MI Multiple Imputations  
NA not applicable  
  
OL-LTE Open -Label, Long -Term Extension study  
P/C phone contact  
[CONTACT_222187]’s Global Assessment  
PK Pharmacokinetic (s) 
  
PP per protocol  
PP-NRS  Peak Pruritus -Numeric Rating Scale  
QD once daily  
RBC  red blood cell(s)  
SAE  serious adverse event  
SD standard deviation  
  
TEAE  treatment emergent adverse event  
TF Treatment Failure  
ULN  upper limit of normal  
US [LOCATION_002]  
V visit 
vIGA -AD™ validated Investigator Global Assessment for Atopic Dermatitis  
WBC  white blood cell(s)  
WOCBP  women of child -bearing potential  
  
 
 

Tapi[INVESTIGATOR_222143].: DMVT -505-3101 , Amendment 3 
Dermavant Sciences , Inc.  Clinical Study Protocol  
Confidential  Page | 13 Synopsis        
Name [CONTACT_790]/Company:  
Dermavant Sciences , Inc.  
Name [CONTACT_791]:  
DMVT -505 (tapi[INVESTIGATOR_191753], 1%)  
Name [CONTACT_3261]:   
Tapi[INVESTIGATOR_222145]:  DMVT -505-3101  Phase:  3 Country:  [LOCATION_002] (US)  and Canada  
Title of Study:  
A Phase 3 Efficacy and Safety Study of Tapi[INVESTIGATOR_222148] (s): 
Up to approximately 60 sites in the US and Canada  
Objectives:  
Primary:  
• To evaluate the efficacy of tapi[INVESTIGATOR_191753], 1% once daily (QD) compared with vehicle control in subjects with 
atopic dermatitis (AD)  
Secondary:  
• To further characterize the efficacy of tapi[INVESTIGATOR_191753], 1% QD compared with vehicle control over time  
• To evaluate the safety and tolerability of tapi[INVESTIGATOR_191753], 1% QD in subjects with AD  
• To describe the effect of tapi[INVESTIGATOR_191753], 1% QD on AD symptom severity and the associated impact on daily 
activities and attitudes in subjects with AD  
• To evaluate plasma concentrations of tapi[INVESTIGATOR_222149]:  
This is a double -blind, randomized, vehicle -controlled, Phase  3, multicenter study to evaluate the efficacy and safety of topi[INVESTIGATOR_191788],  1% compared with vehicle  control cream in subjects ages 2 years and above with AD . 
Following a 30-day screening period,  eligible subjects will be randomized at a 2:1  ratio to receive QD treatment with 
tapi[INVESTIGATOR_191755],  1% or vehicle cream.   Subjects will return to the clinic at Weeks 1, 2, 4, and [ADDRESS_266954]’s continued participation in this study.  
Study drug will be dispensed and applied  during the clinic visits and will be admini stered at home between clinic visits as 
instructed by [CONTACT_8786] .  Subjects or their caregivers will be instructed to apply study drug QD to all affected areas, including 
newly appearing lesions and lesions /areas  that improve during the study .  Subject s or caregivers  will apply sufficient study drug to 
cover completely each lesion with a thin layer of study drug and will record the time of study drug application and daily itch score 
(Peak Pruritus -Numeric Rating Scale [PP -NRS]) in a daily diary provided  by [CONTACT_3452] .  (Note  that subjects are allowed , but 
not required , to treat scalp lesions with study d rug; however, efficacy analyses will not include assessment of AD in this area.)  
Subjects or caregivers will be advised  to maintain the approximate dosing time chosen at the beginning of the study for their full 
study participation .  At the phone contacts at Weeks [ADDRESS_266955] -randomization clinic visits and during any planned study phone 
calls.   On clinic visit days, subjects will be instructed/reminded how to apply study drug (except during the final treatment/end -of-
study visits).   During the clinic visits, subjects or caregivers will apply the daily dose of study drug while on -site under the 
supervision of site personnel.   The time of the dose application and assessments will depend on the time of the clinic visit.   
Therefore, the timing of the clinic visit may lead to a change in  the subject’s chosen dosing time  for that day.  
At the end of the [ADDRESS_266956] the option to enroll in a n Open-Label, Long-Term 
Extension  (OL-LTE) study for an additional 48 weeks of treatment.   Subjects who choose not to participate in the OL-LTE study  
or who fail to qualify for participation in the OL-LTE study will complete a Follow -up Visit (Week  9 visit) approximately 1 week 
after the end of treat ment in this study.   Subjects who withdraw from the study before Week  8 will complete an Early Termination 
Visit  and are not eligible for the OL -LTE study . 
Tapi[INVESTIGATOR_222143].: DMVT -505-3101 , Amendment 3 
Dermavant Sciences , Inc.  Clinical Study Protocol  
Confidential  Page | 14 Number of Subjects:  
Approximately 400 subjects ages 2 years and above will be enrolled in the stud y, randomized at a 2:1 ratio to receive tapi[INVESTIGATOR_222150], 1% (approximately 2 67 subjects) or vehicle cream (approximately 1 33 subjects).  Subjects will be stratified so that a 
minimum of 10% will have severe disease (validated Investigator Global Assessment  in Atopic Dermatitis [ vIGA -AD™] = 4) and 
the remainder will have moderate disease (vIGA ADTM = 3).  A minimum of approximately 15% of subjects will be enrolled into 
each of the following age groups: 2 -6 years, 7 -11 years, 12 -17 years, 18 years and above .  Adults 18 years and above will 
comprise a maximum of 20% of enrolled subjects.  
Diagnosis and Main Criteria for Inclusion:  
Inclusion Criteria:  
Each subject must meet all the following criteria to be eligible to participate in the study:  
1. Male and female subjects ages 2 years and above with clinical diagnosis of AD by [CONTACT_222188].  
2. Subjects with AD covering ≥ 5% and ≤ 35% of the body surface area (BSA).  Scalp should be excluded from the BSA 
calculation to determine eligibility during Screeni ng and at Baseline, and for all efficacy assessments.  
NOTE: Subjects with disease only on palms and soles are not eligible.  
3. A vIGA -AD™ score of > 3 at Screening and Baseline (pre -randomization) . 
4. An Eczema Area and Severity Index (EASI) score of > 6 at Screening and Baseline (pre -randomization).  
5. AD present for at least 6 months for ages 6 years old and above or 3 months for ages 2 to 5 years old, confirmed by [CONTACT_222189]/or according to the subject/caregiver report.   
6. Female sub jects of childbearing potential who are engaging in sexual activity that could lead to pregnancy should use one 
of the following acceptable birth control methods while on study and for [ADDRESS_266957] exposure to study drug.   
• Acceptable contracepti on methods include intrauterine device, hormonal contraceptives, barrier method (e.g., 
condom or diaphragm), or surgical sterilization of male partner (vasectomy)  
• Subjects who claim abstinence as their method of contraception are allowed provided they agr ee to use a barrier 
method (e.g., condom or diaphragm) should they become sexually active from Screening to [ADDRESS_266958] dose of study drug  
Non-child -bearing potential is defined as:  
• premenarchal  
• pre-menopausal females with a documented bilater al tubal ligation, bilateral oophorectomy, hysterectomy, or 
hysteroscopic sterilization  
• postmenopausal female with a cessation of menses for at least 12 months without an alternative medical cause; a 
blood sample with follicle stimulating hormone > 40 mIU/ mL is confirmatory in questionable cases  
7. Female subjects of childbearing potential must have a negative  serum  pregnancy test at Screening and a negative urine 
pregnancy test at Baseline (Day 1).  
8. Subject, subject’s parent(s), or legal representative must be  capable of giving written informed consent /assent , which 
includes compliance with the requirements and restrictions listed in the consent/assent form; written informed consent  
must be obtained prior to any study related procedures . 
Exclusion Criteria:  
A subject who meets any of the following criteria will be excluded and considered ineligible for participation in the study:  
1. Concurrent conditions:  
a. Immunocompromised ( e.g., lymphoma, acquired immunodeficiency syndrome) or history or evidence of active 
or latent tuberculosis or human immunodeficiency virus antibody as documented by [CONTACT_96749]/or 
according to the subject/caregiver report ..  
b. Chronic or acute systemic infection requiring treatment with antiparasitics or antiprotozoals, within 4  weeks  
prior to the Baseline visit .  
c. Chronic or acute systemic bacterial infection requiring treatment with systemic antibiotics within one week prior 
to the Baseline visit.  
Tapi[INVESTIGATOR_222143].: DMVT -505-3101 , Amendment 3 
Dermavant Sciences , Inc.  Clinical Study Protocol  
Confidential  Page | 15 d. Chronic or acute superfic ial fungal infection requiring treatment with systemic antifungals within one week prior 
to the Baseline visit . 
e. Acute active bacterial, fungal, or viral (herpes simplex, herpes zoster, chicken pox) skin infection within 1 week 
prior to the Baseline visit; the condition should be completely resolved one week pr ior to Baseline Visit . 
f. Significant dermatologic or inflammatory condition other than AD that, in the Investigator’s opi[INVESTIGATOR_1649], would 
make it difficult to interpret data or assessments during the study.  For example, s ubjects with an active skin 
condition suc h as Kaposi's varicelliform eruption, scabies, molluscum contagiosum, impetigo, psoriasis, severe 
acne, connective tissue disorder, or  Netherton's syndrome, or any other concurrent active disease .  
g. Concurrent skin lesions in the treatment area or pruritus due to conditions other than AD that, in the opi[INVESTIGATOR_15960], would either interfere with study evaluations or affect the safety of the subject.  
2. Screening alanine aminotransferase (ALT) or aspartate aminotransferase (AST)  ≥ 2.0 x the upper limi t of normal (ULN).  
3. Screening total bilirubin > 1.5x ULN; total bilirubin >  1.5x ULN is acceptable if bilirubin is fractionated and direct 
bilirubin < 35%.  
4. Current or chronic history of liver disease, known hepatic or biliary abnormalities (with the excep tion of Gilbert’s 
syndrome or asymptomatic gallstones), presence of hepatitis B surface antigen (HBsAg), or positive hepatitis C antibody 
test result, or presence of anti -hepatitis B core antigen (anti -HBc).  Subjects having a negative HBsAg and a positive  
anti-HBc may enroll if they have a positive anti -hepatitis B surface antigen demonstrating natural immunity.  Subjects 
with a history of hepatitis C virus i nfection who were medically cured and have an undetectable viral load are eligible to 
enroll.  Subj ects with a history of stable non -alcoholic fatty liver disease without evidence of active inflammation 
(elevated ALT/AST ≥  2.0x ULN) or cirrhosis are eligible to enroll.  
5. Current or a history of cancer within 5  years except for adequately treated skin basa l cell carcinoma, cutaneous  squamous 
cell carcinoma or carcinoma in situ of the cervix (surgical excision or electrodessication and curettage).  
6. Subjects who would not be considered suitable for topi[INVESTIGATOR_8588] (e.g., those with extensive disease involveme nt over a 
large BSA who would be candidates for systemic therapy).  
7. Use of any prohibited medication or procedure within the indicated period before the Baseline visit.  
NOTE :  Prohibited concomitant medications, therapy, etc. during the defined period are as listed in the bullets below.  If 
a subject requires any of these medications throughout the study period, he/she may be excluded from or discontinued 
from the study, at the discretion of the Investigator and Medical Monitor.  
a. From 4 months prior to Baseline until the completion of the Follow -up visit or study discontinuation:   
o DUPI[INVESTIGATOR_24786]® (dupi [INVESTIGATOR_12458] ) injection .  
o Any monoclonal antibody product that becomes approved for AD during the course of the trial.  
b. From 28 days prior to Baseline u ntil the completion of the Follow -up visit or discontinuation:   
o Oral, injectable, and suppository preparations of c orticosteroid s.  Eye drops and nasal preparations are 
allowed.  Inhaled preparations are allowed when used for a stable condition and stable dose for > 28 
days before Screening and are continued at the same dose throughout the study.  
o Oral preparations and injections of immunosuppressants (cyclosporine, methotrexate, azathioprine, 
tacrolimus, Janus kinase inhibitors, etc.). 
o Excessive sun exposure, tanning booth, other ultraviolet light source and phototherapy including 
psoralen and ultraviolet A therapy or is unwilling to minimize natural and artificial sunlight exposure.   
o Treatment with antivirals with the exception of short -term treatmen t for acute upper respi[INVESTIGATOR_190318] (i.e., influenza) or viral suppressive therapy for a history of recurrent herpes labialis or 
genital herpes . 
c. From 14  days prior to Baseline  until the completion of the Follow -up visit or discontinuation:  
o EUCR ISA® (crisaborole) and any other PDE4 inhibitor . 
o Tacrolimus  ointment  and pi[INVESTIGATOR_71861].  
o Topi[INVESTIGATOR_222151] (e.g.,  fluocinonide, triamcinolone 
acetonide ) or super -high potency (e .g., clobetasol propi[INVESTIGATOR_222152]).  Eye drops and nasal preparations are 
allowed.  
Tapi[INVESTIGATOR_222143].: DMVT -505-3101 , Amendment 3 
Dermavant Sciences , Inc.  Clinical Study Protocol  
Confidential  Page | 16 o Coal tar products (on the body) .  If subject chooses to treat scalp with study drug, then coal tar products 
are prohibited for use on the scalp.  
o Over the counter or herbal medicines for AD (topi[INVESTIGATOR_222153]) .  If subjects are using 
emollients, they may continue to use the same emollient on nonlesional skin  during the study .  
Emollients containing salicylic acid are prohibited during the study.  
d. From 7  days prior to Baseline  until the completion of the Follow -up visit or discontinuation:  
o Topi[INVESTIGATOR_222154] (e.g., desonide, hydrocortisone).    
o Oral, injectable, or intravenous antibiotics  or antifungal medications . 
o Topi[INVESTIGATOR_2855] d oxepin, topi[INVESTIGATOR_222155] , or topi[INVESTIGATOR_222156] . 
NOTE : Oral doxepin is allowed for treatment of depression if subject has been on a stable dose (4 
weeks) at Screening . 
o Topi[INVESTIGATOR_57961], except for the treatment of follicul ar events . 
o Antihistamines/an tiallergics (oral, topi[INVESTIGATOR_222157]):  diphenhydramine, chlorpheniramine 
maleate , hydroxyzine.  
NOTE :  The following antihistamines are allowed from Screening  throughout the treatment period: 
loratadine, fexofenadine hydrochloride, cetirizine hydroch loride.   Subjects are allowed to switch from 
non-allowed antihistamines to allowed antihistamines during Screening  but must be on a stable dose for 
[ADDRESS_266959] dosing day 
in the current study:  Minimum of [ADDRESS_266960] (whichever is longer).  
8. A history of or ongoing serious illness or medical, physical, or psychiatric condition(s) that, in the Investigator’s opi[INVESTIGATOR_1649] , 
may interfere with the subject’s participation in the study, interpretation of results, safety of the subject or ability to 
under stand and give informed consent.   
9. Pregnant females as determined by [CONTACT_222190] (Screening) or urine (Baseline) human chorionic gonadotropin test.  
10. Lactating females.  
11. History of sensitivity to the study medications, or components thereof or a history of drug or other allergy that, in the 
opi[INVESTIGATOR_24245], contraindicates their participation.  
12. Previous known participation in a clinical study with tapi[INVESTIGATOR_191752] (previously known as [COMPANY_004]2894512 and WBI -1001).  
Investigational Pro duct, Dosage and Mode of Administration:  
Tapi[INVESTIGATOR_191753], 1%  
 is to be administered by [CONTACT_423]/caregiver QD via topi[INVESTIGATOR_55594] a th in layer to affected areas.  
Reference Therapy, Dosage and Mode of Administration:  
Vehicle cream  is to be administered by [CONTACT_423]/caregiver QD via 
topi[INVESTIGATOR_55594] a thin layer to affected areas.  
Duration of Treatment:  
• Subjects randomized to tapi[INVESTIGATOR_191753], 1% will receive tapi[INVESTIGATOR_222158] 8 weeks  
• Subjects randomized to vehicle cream will receive vehicle for [ADDRESS_266961] not to enroll in that study is up to 13 weeks in total (including 
up to 30 days screening, 8 weeks treatment, and a 1 -week follow -up period).  

Tapi[INVESTIGATOR_222143].: DMVT -505-3101 , Amendment 3 
Dermavant Sciences , Inc.  Clinical Study Protocol  
Confidential  Page | 17 Criteria for Evaluation:  
Efficacy Assessments:  • vIGA -AD™  
• EASI  
• Percentage of total body surface area (%BSA) affected  
Functional Outcomes 
and Quality of Life 
Assessments:  • PP-NRS, for completion by [CONTACT_222191] > 12 years and for completion by [CONTACT_222192] < 12 years  
•   
  
 
  
•  
•  
 
Pharmacokinetic 
Assessments:  • Plasma concentrations of tapi[INVESTIGATOR_222159]:  • Adverse events ( AEs) 
• Vital signs  
• Physical examinations  
• Clinical laboratory tests  
• Electrocardiograms (ECGs)  
• Investigator -assessed Local Tolerability Scale (LTS)  
• Subject (or caregiver) -assessed LTS  
Study Endpoints:  
Primary:  
• Proportion of subjects who have a vIGA -AD™ score of clear or almost clear (0 or 1) and at least a 2 -grade 
reduction from Baseline at Week 8.   
Secondary:  
• Proportion of subjects with ≥ 75% improvement in EASI from Baseline at Week 8  
• Mean change in %BSA affected from Baseline at Week 8  
• Proportion of subjects with ≥ 90% improvement in EASI from Baseline at Week 8  
• Proportion of subjects > 12 years old with a Baseline  PP-NRS score > 4 who achieve ≥ 4 -point reduction in the 
PP-NRS from Baseline at Week 8  
Exploratory:  
    
   
 
   
  
   
  
  
  
  
  
  
    
 

Tapi[INVESTIGATOR_222143].: DMVT -505-3101 , Amendment 3 
Dermavant Sciences , Inc.  Clinical Study Protocol 
Confidential  Page | 21 Procedures and Assessment  Screening  Baseline  Double -Blind Vehicle -Controlled Treatment Phase  FUa ETb 
V1 V2 V3 V4 P/Cc V5 P/Cc V6 V7 NA 
Day -30 
to 
Day -1 Day 1  Week  1 
Day 8 
(±2 d) Week  2 
Day 15 
(±2 d) Week  3 
Day 22 
(±2 d) Week  4 
Day 29 
(±2 d) Week  6 
Day 43 
(±2 d) Week  8 
Day 57 
(±2 d) Week  9 
Day 64 
(±2 d) NA 
PP-NRS  (pre-dose)s X X X X X X X 
 
 
LTSr X X X X X X 
Dispense (D)/collect (C) diaryt D C/D C/D C/D C C 
Review subject diaries for treatment compliance  X X X X X 
Dispense (D)/Collect (C) study drug D C/D C/D C/D C C 
Review instructions  for study drug applicationu X X X X X X 
Study drug application under supervisionv X X X X 
Enrollment (optional) in OL -LTE study X 
a. The Follow -up Visit will be performed for any subject who completes Visit 6/Week [ADDRESS_266962] who early terminates .
b. Subjects who withdraw from the study before Visit 6 (Week 8) will complete an Early Termination Visit.  A follow -up visit is not required for a subject who early terminates.
c. Phone calls to assess AEs and concomitant medications, to review study drug application procedures, and to confirm subject ’s continued participation in the study.  Subjects should
be reminded to complete the diary and bring it with them to the next clin ic visit.
d. Medical history will include year of AD diagnosis, CV family history, allergic conditions, and risk factors (including hei ght, weight, medical conditions) and family history of liver
disease.   As part of the subject’s medical history, all syst emic (oral and injectable) medications used by [CONTACT_222193] [ADDRESS_266963] to be performed before randomization.
h. Physical examination will include height and weight (BMI will be calc ulated in the CRF ) at the Screening visit; a brief physical examination will be performed at other visits.
i. Vital signs will include blood pressure, pulse rate, and body temperature and should be measured after the subject is seat ed for at least 5 minutes.  Vital signs will be measured before
blood collection for clinical laboratory assessments and PK analysis  (where applicable) .
j. ECGs will be collected in a subset of subjects and will be collected prior to study drug administration in clinic.  Inf ormed consent/assent will be required.
k. Includes serum chemistry and liver chemistry tests, and hematology.
l.Blood sample collection for clinical laboratory tests is not required at the Baseline Visit if it has been ≤14 days since sam ples were collec ted at Screening and the results of those
clinical laboratory tests were not clinically significant .
m.If needed, laboratory testing at the Follow -up visit for ongoing AEs or abnormal laboratory values.

Tapi[INVESTIGATOR_222143].: DMVT -505-3101 , Amendment 3 
Dermavant Sciences , Inc.  Clinical Study Protocol  
Confidential  Page | 24  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
1.1.2 Study Rationale   
This pi[INVESTIGATOR_9205]  3 study is being conducted as part of a clinical development program to evaluate the 
efficacy and safety of tapi[INVESTIGATOR_191753], 1% for the topi[INVESTIGATOR_222160] [ADDRESS_266964] registration in the [LOCATION_002]  and 
Canada . 
1.2 Rationale for Study Design, Dose, and Control Groups   
This study is an 8 -week double -blind, vehicle -controlled treatment study in which subjects will be 
randomized to receive tapi[INVESTIGATOR_191753], 1% or vehicle cream QD for 8  weeks.  The study will be conducted at 
multiple study sites in more than one  country to enhance the possibility of inclusion of a wider range of 
population groups and to increase generalizability of the results.  
This randomized, double -blind, vehicle -controlled study design will minimize the potential for subjecti ve bias 
related to possible identification of which subjects are receiving active treatment and will minimize selection 
and allocation bias by [CONTACT_222194].  A vehicle control group is included to provide a 

Tapi[INVESTIGATOR_222143].: DMVT -505-3101 , Amendment 3 
Dermavant Sciences , Inc.  Clinical Study Protocol  
Confidential  Page | 25 control for comparison and to ensure study sensitivity for characterization of the safety and efficacy profile of 
tapi[INVESTIGATOR_191753], 1%.  
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 

Tapi[INVESTIGATOR_222143].: DMVT -505-3101 , Amendment 3 
Dermavant Sciences , Inc.  Clinical Study Protocol  
Confidential  Page | [ADDRESS_266965] refer to the 
current version of the tapi[INVESTIGATOR_222161]’s Brochure for detailed information regarding warnings, 
precautions, contraindications, AEs, and other signifi cant data pertaining to the study drug being used in this 
study.  

Tapi[INVESTIGATOR_222143].: DMVT -505-3101 , Amendment 3 
Dermavant Sciences , Inc.  Clinical Study Protocol  
Confidential  Page | 28    
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
1.3.2 Benefit Assessment   
Subjects may experience improvements in their AD during the course of the study and may benefit from the 
additional safety assessments conducted as part of the study (e.g., physical examinatio n, laboratory tests).  
Subjects in the study will also contribute to the process of developi[INVESTIGATOR_007] a novel anti -inflammatory agent for the 
topi[INVESTIGATOR_166474].  
1.3.3 Overall Benefit Risk   
Taking into account the measures taken to minimize risk to subjects in this study, the potential risks identified 
in association with tapi[INVESTIGATOR_222162].  

Tapi[INVESTIGATOR_222143].: DMVT -505-3101 , Amendment 3 
Dermavant Sciences , Inc.  Clinical Study Protocol  
Confidential  Page | 29 2 Objectives and Endpoints   
The objectives and associated endpoints of the study are as follows:  
Objectives  Associated Endpoint  
Primary  
• To evaluate the efficacy of 
tapi[INVESTIGATOR_191753], 1% QD 
compared with vehicle 
control in subjects with AD  • Proportion of subjects who have a validated Investigator Global Assessment in Atopic 
Dermatitis (vIGA -AD™) score of clear or almost clear (0 or 1) and at least a 2 -grade 
reduction from Baseline at Week 8.   
Secondary/Exploratory  Secondary:  
• To further characterize the 
efficacy of tapi[INVESTIGATOR_191753], 
1% QD compared with 
vehicle control over time  • Proportion of subjects with ≥ 75% improvement in EASI from Baseline at  Week  8 
• Mean change in %BSA affected from Baseline at Week 8  
• Proportion of subjects with ≥ 90% improvement in EASI from Baseline at Week 8  
• Proportion of subjects > 12 years old with a Baseline Peak Pruritus -Numeric Rating Scale 
(PP-NRS ) score > 4 who achieve ≥ 4 -point  reduction in the PP -NRS  from Baseline at 
Week  8 
Exploratory:  
    
   
 
  
  
   
  
  
  
  
   
   
    
 
  
 
  
 
• To evaluate the safety and 
tolerability of tapi[INVESTIGATOR_222150], 1% QD in subjects 
with AD  • Incidence, frequency, and duration of TEAEs and serious adverse events (SAEs)  
• Change from Baseline in laboratory values  
• Change from Baseline in ECG parameters  
• Change from Baseline in vital signs  
• Mean Investigator -assessed local tolerability scale ( LTS) scores by [CONTACT_765] (overall and  
sensitive areas ) 
• Mean subject (or caregiver) -assessed LTS scores by [CONTACT_765]  
• To describe the effect of 
tapi[INVESTIGATOR_191753], 1% QD on 
AD symptom severity and 
the associated impact on 
daily activities and attitudes 
in subjects with AD •   
  
 
•  
  
•  
 

Tapi[INVESTIGATOR_222143].: DMVT -505-3101 , Amendment 3 
Dermavant Sciences , Inc.  Clinical Study Protocol  
Confidential  Page | 30 Objectives  Associated Endpoint  
•  
 
•  
• To evaluate  plasma 
concentrations of tapi[INVESTIGATOR_222163]   • Plasma concentration of tapi[INVESTIGATOR_222164] 4  and 8  

Tapi[INVESTIGATOR_222143].: DMVT -505-3101 , Amendment 3 
Dermavant Sciences , Inc.  Clinical Study Protocol  
Confidential  Page | 31 3 Study Design   
3.1 Overall Design   
This is a double -blind, randomized, vehicle -controlled, Phase  3, multicenter study to evaluate the efficacy and 
safety of topi[INVESTIGATOR_222165], 1% compared with vehicle cream  in children  and adult subjects with AD.   
Following a 30 -day screening period, eligible subjects will be randomized at a 2:1  ratio to receive QD 
treatment with tapi[INVESTIGATOR_191755],  1% or vehicle cream for [ADDRESS_266966]’s continued particip ation in this study.  
Study drug will be dispensed and applied during the clinic visits and will be administered at home between 
clinic visits as instructed by [CONTACT_8786].  Subjects or their caregivers will be instructed to apply study drug 
QD to all af fected areas, including newly appearing lesions and lesions/areas that improve during the study.  
Subjects or their caregivers will apply sufficient study drug to cover completely each lesion with a thin layer 
of study drug and will record the time of stud y drug application and daily itch score (PP-NRS ) in a daily diary 
provided by [CONTACT_3452].  Subjects are allowed, but not required, to treat scalp lesions with study drug; 
however, efficacy analyses will not include assessment of AD in this area.  Subje cts and/or caregivers will be 
advised  to maintain the approximate dosing time chosen at the beginning of the study for their full study 
participation.  Nonmedicated emollients that do not contain salicylic acid may be used on nonlesional skin  but 
the subje ct (or caregiver) should wait at least 30 minutes after applying study drug before applying 
nonmedicated emollients ; emollients should not be applied to lesional skin during treatment.  The same 
emollient should be used throughout the subject’s participation in the study.   At the phone contacts at Weeks 
[ADDRESS_266967] -randomization clinic visits and during any 
planned study phone calls.  On clinic visit days, subjects and/or caregivers will be instructed/reminded on how 
to apply study drug (except during the final treatment/end -of-study visits).  During the clinic visits , subjects or 
their caregivers will apply the daily dose of study drug while on -site under the supervision of site personnel 
after efficacy and safety assessments have been completed , with the exception of the LTS at some visits (as 
outline d in the Schedul e of Assessments [ Table 1]).  The time of the dose application and assessments will 
depend on the time of the clinic visit.  Therefore, the timing of th e clinic visit may lead to a change in the 
subject’s chosen dosing time for that day.  
At the end of the [ADDRESS_266968] the option to enroll in an Open -
Label, Long -Term Extension (OL -LTE) study for an additional 4 8 weeks.  Subjects who complete Visit 
6/Week 8 but choose not to participate in the OL -LTE study or who fail to qualify for participation in the 
OL-LTE study will complete a Follow -up Visit (Visit 7/Week  9 visit) approximately 1  week after the end of 
treatm ent in this study.  Subjects who withdraw from the study before Visit 6/Week  [ADDRESS_266969] not to enroll in that study is 
Tapi[INVESTIGATOR_222143].: DMVT -505-3101 , Amendment 3 
Dermavant Sciences , Inc.  Clinical Study Protocol  
Confidential  Page | 33 4 Study Population   
4.1 Type and Number of Subjects   
Approximately 400 adult and pediatric subjects ages 2 years and above with AD will be enrolled in the  study 
at approximately 60 study sites in the US and Canada.  A minimum of approximately 15% of subjects will be 
enrolled into each of the following age groups:  2 -6 years, 7 -11 years, 12 -17 years, 18 years and above.   
Adults 18 years and above will compri se a maximum of 20% of enrolled subjects.  
Protocol violations from inclusion and exclusion criteria are prohibited because ineligible study subjects can 
potentially jeopardize the scientific integrity of the study, regulatory acceptability, or subject safe ty.  
Therefore, adherence to the criteria as specified in the protocol is essential.  
4.[ADDRESS_266970] meet all of the following criteria to be eligible to par ticipate in the study:  
1. Male and female subjects ages 2 years and above with clinical diagnosis of AD by [CONTACT_222195] [ Hanifin , 1980] (see Appendix 1 ). 
2. Subjects with AD covering ≥ 5% and ≤ 35% of the BSA.  Scalp should be excluded from the BSA 
calculation to determine eligibility during Screening a nd at Baseline, and for all efficacy assessments.  
NOTE: Subjects with disease only on palms and soles are not eligible.  
3. A vIGA -AD™ score of > 3 at Screening and Baseline (pre -randomization) . 
4. An EASI score of > 6 at Screening and Baseline (pre -randomizatio n). 
5. AD present for at least 6 months for ages 6 years old and above or 3 months for ages 2 to 5 years old, 
confirmed by [CONTACT_222196]/or according to the subject/caregiver report.  
6. Female subjects of childbearing potential who are engaging  in sexual activity that could lead to 
pregnancy should use one of the following acceptable birth control methods while on study and for [ADDRESS_266971] exposure to study drug.    
• Acceptable contraception methods include intrauterine device, hormonal  contraceptives, barrier 
method (e.g., condom or diaphragm), or surgical sterilization of male partner (vasectomy)  
• Subjects who claim abstinence as their method of contraception are allowed  provided they agree to 
use a barrier method (e.g., condom or diap hragm) should they become sexually active from 
Screening to [ADDRESS_266972] dose of study drug  
Non-child -bearing potential is defined as:  
• premenarchal  
• pre-menopausal females with a documented bilateral tubal ligation, bilateral oophorectomy, 
hysterectomy, or hysteroscopic sterilization  
• postmenopausal female with a cessation of menses for at least 12 months without an alternative 
medical cause; a blood sample with follicle stimulating hormone > 40 mIU/mL is confirmatory in 
questionable cases  
7. Female subjects of childbearing potential must have a negative serum pregnancy test at Screening and 
a negative urine pregnancy test at Baseline (Day  1). 
Tapi[INVESTIGATOR_222143].: DMVT -505-3101 , Amendment 3 
Dermavant Sciences , Inc.  Clinical Study Protocol  
Confidential  Page | [ADDRESS_266973]’s parent(s), or legal representative must be capable of giving written informed 
consent /assent , which includes compliance with the requirements and restrictions listed in the 
consent/assent form; written informed consent must be obtained prior to any study related procedures.  
4.[ADDRESS_266974] who meets any of the following criteria will be excluded and considered ineligible for participation 
in the study:  
1. Concurrent conditions:  
a. Immunocompromised (e.g., lymphoma, acquired immunodeficiency syndrome) or history or 
evidence of active or latent tuberculosis or human immunodeficiency virus antibody as 
documented by [CONTACT_70266]/or according to the subject/caregiver report .  
b. Chronic or acute systemic infection requiring treatment with antiparasitics, or antiprotozoals, 
within 4 weeks prior to the Baseline visit.  
c. Chronic or acute systemic bacterial infection requiring treatment with systemic antibiotics within 
one week prior t o the Baseline visit.  
d. Chronic or acute superficial fungal infection requiring treatment with systemic antifungals within 
one week prior to the Baseline visit  
e. Acute active bacterial, fungal, or viral (herpes simplex, herpes zoster, chicken pox) skin infect ion 
within 1 week prior to the Baseline visit; the condition should be completely resolved one week 
prior to Baseline Visit  
f. Significant dermatologic or inflammatory condition other than AD that, in the Investigator’s 
opi[INVESTIGATOR_1649], would make it difficult to int erpret data or assessments during the study.  For example, 
subjects with an active skin condition such as Kaposi's varicelliform eruption, scabies, molluscum 
contagiosum, impetigo, psoriasis, severe acne, connective tissue disorder, or  Netherton's 
syndrome , or any other concurrent active disease.  
g. Concurrent skin lesions in the treatment area or pruritus due to conditions other than AD that, in 
the opi[INVESTIGATOR_689], would either interfere with study evaluations or affect the safety of 
the subject.  
2. Screening alanine aminotransferase (ALT) or aspartate aminotransferase (AST)  ≥ 2.0 x the upper limit 
of normal (ULN).  
3. Screening total bilirubin > 1.5x ULN; total bilirubin >  1.5x ULN is acceptable if bilirubin is 
fractionated and direct bilirubin < 35%.  
4. Current or chronic history of liver disease, known hepatic or biliary abnormalities (with the exception 
of Gilbert’s syndrome or asymptomatic gallstones), presence of hepatitis B surface antigen (HBsAg), 
or positive hepatitis C antibody test result, or pr esence of anti -hepatitis B core antigen (anti -HBc).  
Subjects having a negative HBsAg and a positive anti -HBc may enroll if they have a positive anti -
hepatitis B surface antigen demonstrating natural immunity.  Subjects with a history of hepatitis C 
virus  infection who were medically cured and have an undetectable viral load are eligible to enroll.  
Subjects with a history of stable non -alcoholic fatty liver disease without evidence of active 
inflammation (elevated ALT/AST ≥ 2.[ADDRESS_266975]) or cirrhosis are elig ible to enroll.  
Tapi[INVESTIGATOR_222143].: DMVT -505-3101 , Amendment 3 
Dermavant Sciences , Inc.  Clinical Study Protocol  
Confidential  Page | 35 5. Current or a history of cancer within 5  years except for adequately treated cutaneous  basal cell 
carcinoma, squamous cell carcinoma or carcinoma in situ of the cervix (surgical excision or 
electrodessication and curettage).  
6. Subjects who wo uld not be considered suitable for topi[INVESTIGATOR_8588] (e.g., those with extensive disease 
involvement over a large BSA who would be candidates for systemic therapy).  
7. Use of any prohibited medication or procedure within the indicated period before the Baseline  visit.  
NOTE :  Prohibited concomitant medications, therapy, etc. during the defined period are as listed in the 
bullets below.  If a subject requires any of these medications throughout the study period, he/she may 
be excluded from or discontinued from th e study, at the discretion of the Investigator and Medical 
Monitor.  
a. From 4 months prior to Baseline until the completion of the Follow -up visit or study 
discontinuation:  
− DUPI[INVESTIGATOR_24786]® (dupi [INVESTIGATOR_12458] ) injection.  
− Any monoclonal antibody product that becomes approved for AD during the course of the trial.  
b. From 28 days prior to Baseline until the completion of the Follow -up visit or discontinuation:  
− Oral, injectable, and suppository preparations of corticosteroids.  Eye drops and nasal 
preparations are allowed .  Inhaled preparations are allowed when used for a stable condition 
and stable dose for > 28 days before Screening and are continued at the same dose throughout 
the study.  
− Oral preparations and injections of immunosuppressants (cyclosporine, methotrexate , 
azathioprine, tacrolimus, Janus kinase inhibitors, etc.).  
− Excessive sun exposure, tanning booth, other ultraviolet light source and phototherapy 
including psoralen and ultraviolet A therapy or is unwilling to minimize natural and artificial 
sunlight expo sure.  
− Treatment with antivirals with the exception of short -term treatment for acute upper respi[INVESTIGATOR_222166] (i.e., influenza) or viral suppressive therapy for a history of recurrent herpes 
labialis or genital herpes.  
c. From 14  days prior to Base line until the completion of the Follow -up visit or discontinuation:  
− EUCRISA® (crisaborole) and any other PDE4 inhibitor.  
− Tacrolimus ointment and pi[INVESTIGATOR_71861].  
− Topi[INVESTIGATOR_222151] (e.g.,  fluocinonide , 
triamcinolone acetonide) or super -high potency (e.g., clobetasol propi[INVESTIGATOR_16847]).  Eye drops and 
nasal preparations are allowed.  
− Coal tar products (on the body).  If subject chooses to treat scalp with study drug, then coal tar 
products are prohibited for u se on the scalp.  
− Over the counter or herbal medicines for AD (topi[INVESTIGATOR_222153]).  If subjects are 
using emollients, they may continue to use the same emollient on nonlesional skin during the 
study.  Emollients containing salicylic acid are pro hibited during the study.  
d. From 7  days prior to Baseline  until the completion of the Follow -up visit or discontinuation:  
Tapi[INVESTIGATOR_222143].: DMVT -505-3101 , Amendment 3 
Dermavant Sciences , Inc.  Clinical Study Protocol  
Confidential  Page | 36 − Topi[INVESTIGATOR_222167] (e.g., desonide, hydrocortisone).    
− Oral, injectable, or intravenous antibi otics or antifungal medications.  
− Topi[INVESTIGATOR_222168], topi[INVESTIGATOR_222169], or topi[INVESTIGATOR_222156] . 
NOTE : Oral doxepin is allowed for treatment of depression if subject has been on a stable dose 
(4 weeks) at Screening . 
− Topi[INVESTIGATOR_57961], exc ept for the treatment of follicul ar events  
− Antihistamines/antiallergics (oral, topi[INVESTIGATOR_222157]):  diphenhydramine, chlorpheniramine 
maleate, hydroxyzine.  
NOTE :  The following antihistamines are allowed from Screening throughout the treatment 
period: loratadine, fexofenadine hydrochloride, cetirizine hydrochloride.  Subjects are allowed 
to switch from non -allowed antihistamines to allowed antihistamines during Sc reening  but 
must be on a stable dose for [ADDRESS_266976] dosing day in the current study:  [ADDRESS_266977] 
(whichever is longer).  
8. A history of or ongoing serious illness or medical, physical, or psychiatric condition(s) that, in the 
Investigator’s opi[INVESTIGATOR_1649], may interfere with the subject’s participation in the study, interpretation of 
results, or ability to understand and give informe d consent.  
9. Pregnant females as determined by [CONTACT_222190] (Screening) or urine (Baseline) human chorionic 
gonadotropin test.  
10. Lactating females.  
11. History of sensitivity to the study medications, or components thereof or a history of drug or other 
allergy that, in the opi[INVESTIGATOR_24245], contraindicates their participation.  
12. Previous known participation in a clinical study with tapi[INVESTIGATOR_191752] (previously known as [COMPANY_004]2894512 
and WBI -1001).  
4.[ADDRESS_266978] avoid  ultraviolet  light, phototherapy, and excessive sun exposure throughout the study.  When 
prolonged exposure cannot be avoided, use of sunscreen products (except on AD lesions) and pro tective 
apparel are recommended.  
4.5 Screening/Baseline Failures   
To determine subject eligibility at Screening and Baseline, a single repeat of tests or procedures may be 
allowed dur ing the screening period at the discretion of the Investigator; the Medical Monitor should be 
consulted if needed.    
Screen failures are defined as subjects who consent to participate in the clinical study but are not subsequently 
randomized within the sc reening time period.  A minimal set of screen failure information is required to 
ensure transparent reporting of screen failure subjects to meet the Consolidated Standards of Reporting Trials 
publishing requirements and to respond to queries from regulator y authorities.  Minimal information includes 
demography, screen failure details, eligibility criteria, and any AEs /SAEs . 
Tapi[INVESTIGATOR_222143].: DMVT -505-3101 , Amendment 3 
Dermavant Sciences , Inc.  Clinical Study Protocol  
Confidential  Page | [ADDRESS_266979] who screen fails may be allowed to re -screen one time at the discretion of the Investigator ; the 
Medical Monitor  should be co nsulted if needed . 
4.[ADDRESS_266980] may voluntarily discontinue treatment and/or withdraw from participation in this study at any time 
at his/her own request or  may be discontinued from study treatment at any time at the discretion of the 
Investigator for safety, behavioral, compliance, or administrative reasons.  Subjects withdrawn from the study 
will not be replaced.  
4.6.[ADDRESS_266981] withdrawn from the study for any of the following reasons:  
• Subject has an AE that is considered to be related to study drug or procedures AND  is severe 
enough to warrant treatment discontinuation, as determined by [CONTACT_737] (Section  8.1). 
• Pregnancy  
• Any Grade 3  or 4 AE, based on Cancer Institute Common Terminology Criteria for Adverse 
Events (CTCAE) criteria,  considered c ausally related to study drug (Section  8.2.2 ) 
Study dr ug may be discontinued and the subject withdrawn from the study for any of the following reasons:  
• Subject requires concurrent prohibited medication during the study  (Section 5.6.2 ).  Nonmedicated 
emollients that do not contain salicylic acid may be used on nonlesional skin  but the subject (or 
caregiver) should wait at least 30 minutes after applying study drug before applying nonmedicated 
emollients ; emollients should not be applied to lesional skin during treatment.  The same emollient 
should be used throughout the subject’s participation in the study.  
NOTE : If, in the opi[INVESTIGATOR_191794], such medication will 
not interfere with the conduct or interpretation of the study or compromise the safety of the 
subject, then the subject may continue to receive study drug.  If the subject is permanently 
discontinued from study drug, they may remain in the study for safety asse ssments as needed, at 
the discretion of the Investigator and Medical Monitor, but they are not eligible to enroll in the 
OL-LTE.  
• Subject noncompliance  
• Investigator noncompliance  
• Discontinuation of the study at the request of the Sponsor, regulatory agency,  or an Institutional 
Review Board (IRB)/Independent Ethics Committee (IEC).  
If a subject meets a withdrawal criterion during treatment, an Early Termination visit will be required 
(Section  7.9). 
4.6.2 Withdrawal Procedures   
The primary reason for the discontinuation of study drug and/or withdrawal from study must be recorded in 
the source document and on the case report form (CRF).  If a subject is prematurely discontinued from study 
drug, the Investigator must make every effort to perform an Early Termination Visit ( Section  7.9) and 
document the primary reaso n for withdrawal.  
Tapi[INVESTIGATOR_222143].: DMVT -505-3101 , Amendment 3 
Dermavant Sciences , Inc.  Clinical Study Protocol  
Confidential  Page | [ADDRESS_266982] to follow -up if he/she repeatedly fails to return to the study site for scheduled 
visits and is unable to be cont acted by [CONTACT_3452].  The following actions must be taken if a subject fails to 
return to the clinic for a required study visit:  
• The site must attempt to contact [CONTACT_222197], counsel the subject on the importance of maintaining the assigned visit schedule, and 
ascertain whether or not the subject wishes to and/or should continue in the study.  
• Before a subject is deemed lost to follow -up, the Investigator or designee must make every effort 
to regain contact [CONTACT_222198] (where possible, [ADDRESS_266983]’s last known mailing address or local equivalent methods).  These 
contact [CONTACT_9300]’s  medical record.  
• Should the subject or caregiver continue to be unreachable, he/she will be considered to have 
withdrawn from the study with a primary reason of lost to follow -up.  In this case, the 
discontinuation date will be listed as the date the cert ified letter was mailed to the subject.  
Tapi[INVESTIGATOR_222143].: DMVT -505-3101 , Amendment 3 
Dermavant Sciences , Inc.  Clinical Study Protocol  
Confidential  Page | 40 • QD application to affected areas; subjects or their caregivers are advised to choose the application 
time they prefer and to apply the study drug at that approximate time each day of study 
participa tion.  Subjects should avoid dosing around midnight to avoid potentially dosing twice in 
one calendar day.  
• If a subject misses a daily dose, it will be recorded as a protocol deviation.  The subject should 
continue dosing the next day and should not apply more than once daily to make up for the missed 
dose on the previous day.  If a dose is missed, the missed d ose and the reason for the missed dose 
should be recorded in the daily diary as such.  Itch rating can still be recorded in the diary even if a 
daily dose was missed.  
• Study drug should be applied to dry, clean skin.  
• Study drug may be applied to skin around  the eye but avoid direct contact [CONTACT_222199] – study 
drug is not for ophthalmic use.  
• Wash hands after application, unless treating lesions on the hands.  
• Study drug should be applied to all lesions, including newly appearing lesions and lesions that 
have improved or resolved during the study.  A body diagram identifying locations of lesions may 
be provided to the subject and/or caregiver.  
• Subjects are allowed, but not required, to treat scalp lesions with study drug; however, efficacy 
analyses will not in clude assessment of AD in this area.   
• If there is residual cream visible on the disease -affected lesional skin, then the subject or caregiver 
should be instructed to continue to lightly rub the cream into the skin until it is no longer visible.  
• If study d rug is applied to the subject by [CONTACT_19015], that person should thoroughly wash 
his/her hands after application.  
• When dosing at home subjects or caregiver should record the time of study drug application in the 
daily diary.  Itch rating should also be recorded in the diary.  
• On clinic visit days, study drug should be applied in the clinic under the supervision of site 
personnel and after safety and efficacy assessments have been completed (except for subject and 
Investigator LTS  at Weeks 1, 2 and 4 ). 
NOT E:  The time of the dose and assessments on clinic visit days will depend on the time of the 
clinic visit.  Therefore, the timing of the clinic visit may differ from the subject’s chosen dosing 
time.  The intention is to allow flexibility to accommodate su bjects’ schedules.  
• Nonmedicated emollients that do not contain salicylic acid may be used on nonlesional skin  but 
the subject (or caregiver) should wait at least 30 minutes after applying study drug before applying 
nonmedicated emollients ; emollients shoul d not be applied to lesional skin during treatment.  The 
same emollient should be used throughout the subject’s participation in the study.  
Subjects and/or caregivers will be instructed/reminded on how to apply study drug at each clinic visit (except 
durin g the final treatment visit).  
5.1.6   
 

Tapi[INVESTIGATOR_222143].: DMVT -505-3101 , Amendment 3 
Dermavant Sciences , Inc.  Clinical Study Protocol  
Confidential  Page | 41   
 
 
 
 
   
 
 
5.2 Randomization/Treatment Assignment   
For the double -blind, vehicle -controlled phase of the stu dy, subjects will be randomized at a ratio of 2:1  to 
receive tapi[INVESTIGATOR_191753], 1% or vehicle cream as follows:  
Randomization in Double -Blind, Vehicle -Controlled Phase  
Regimen  Number of Subjects  
Tapi[INVESTIGATOR_191753], 1% QD for 8 weeks  Approximately 2 67 Subjects  
Vehicle cream QD for 8  weeks  Approximately 1 33 Subjects  
QD = once daily  
Randomization will be stratified by [CONTACT_222200] -AD™ score so that subjects with severe AD ( vIGA -AD™ 
score of 4) will be limited to approximately 10% each of the total randomized population, and the majority of 
the enrolled subjects (approximately 90%) will have a vIGA -AD™  score of 3, signifying moderate disease.   
Randomization will also be stratified b y age so that a minimum of approximately 15% of subjects will be 
enrolled into each of the following age groups:  2 -6 years, 7 -11 years, 12 -17 years, 18 years and above.  
Adults 18 years and above will comprise a maximum of 20% of enrolled subjects.  
The ra ndomization lists will be generated using a validated system, which involves a pseudo -random number 
generator so that the resulting treatment will be  both reproducible and non -predictable.  Access to the codes 
will be controlled and documented.  
5.[ADDRESS_266984] received.  The following conditions will apply for 
breaking the blind:  
• The Investigator or treating physician may unblind a subject’s treatment assignment only in the 
case of  an emergency  OR in the event of a serious medical condition when knowledge of the 
study drug is essential for the appropriate clinical management or welfare of the subject as judged 
by [CONTACT_737].  
• Investigators will contact [CONTACT_1689], who will have direct access to the system for 
unblinding an individual study subject.  
• The Investigator should discuss options with  the Medical Monitor or appropriate study personnel 
before making the decision to unblind the subject’s treatment assi gnment.  

Tapi[INVESTIGATOR_222143].: DMVT -505-3101 , Amendment 3 
Dermavant Sciences , Inc.  Clinical Study Protocol  
Confidential  Page | 42 • If the Sponsor personnel are not contact[CONTACT_222201], the Investigator must notify the 
Sponsor as soon as possible after unblinding, but without revealing the treatment assignment of the 
unblinded subject, unless that information is imp ortant for the safety of subjects currently in the 
study.  
• The date and reason for the unblinding must be fully documented in the CRF.  
• A subject will be withdrawn if the subject’s treatment code is unblinded by [CONTACT_222202].  The p rimary reason for discontinuation (the event or condition which led to the 
unblinding) will be recorded in the source documents and CRF.  
• The Sponsor or their designee may unblind the treatment assignment for any subject with an SAE.  
If the SAE requires th at an expedited regulatory report be sent to one or more regulatory agencies, 
a copy of the report, identifying the subject’s treatment assignment, may be sent to Investigators in 
accordance with local regulations.  
5.[ADDRESS_266985]  or caregiver.  Subjec t 
compliance will be assessed via study diary completion.  
When subjects are dosed at the site, they and/or their caregiver will apply the study drug under supervision of 
the study staff.  The date and time of each dose administered in the clinic will be re corded in the source 
documents.  The study drug and study subject identification should be confirmed at the time of dosing by a 
member of the study site staff other than the person dispensing the study drug.  
At the time of dispensing study drug to each sub ject, site personnel will weigh the tubes to be dispensed with 
the cap on and will record the weight of all tubes dispensed at each visit in the drug accountability logs.  
Subjects and/or caregivers will be instructed to bring all used and unused tubes wit h them to each study visit.  
Site personnel will weigh the returned tubes (used and unused) with the cap on and record the weight in the 
drug accountability logs.  If a tube has been lost, discarded, or forgotten by [CONTACT_423], then the site personnel 
will make a notation of this on the drug accountability logs.  Forgotten tubes should be returned by [CONTACT_222203].  Tubes of study medication dispensed at the most recent prior visit which remain 
unopened (the foil cap on the tube remai ns fully intact/undisturbed) may be re -dispensed to study subjects at 
the current visit.  Unopened tubes may only be re -dispensed once.  Opened, partially used tubes or tubes with 
foil overlay removed are not to be re -dispensed to study subjects.  If there  is any question as to 
re-dispensation, sites should issue new tubes of study medication to the subject(s).  
5.5 Treatment after the End of the Study   
Subjects will not receive any add itional treatment with the study drug from the Sponsor after completion of 
the study (with the exception of eligible subjects who enroll in the OL -LTE study) because the indication 
being studied is not life threatening or seriously debilitating and other t reatment options are available.  
The Investigator is responsible for ensuring that consideration has been given to the post -study care of the 
subject’s medical condition, whether or not the Sponsor is providing specific post -study drug.  
Tapi[INVESTIGATOR_222143].: DMVT -505-3101 , Amendment 3 
Dermavant Sciences , Inc.  Clinical Study Protocol  
Confidential  Page | 43 5.6 Prior and Concomitan t Therapy   
Any medication (including over the counter or prescription medication, vitamins and/or herbal supplements) 
administered to the subject up to [ADDRESS_266986] also 
include name [CONTACT_11889] (generic name, as a general rule), dose, frequency, administration routes, and 
dates of the first and last dose, as applicable.  
The Medical Monitor should be contact[CONTACT_31182].  
5.6.1 Permitted Medications and Nondrug Therapi[INVESTIGATOR_222170] (Week  8) and that the medication is not a prohibited medication as 
described in the Exclusion Criteria (Section  4.3). 
In the ev ent of skin infection, topi[INVESTIGATOR_222171]; however, study drug must not be applied to the area until the skin 
infection is healed.  
Nonmedicated emollients that do not contain salicylic acid may be used on nonlesional skin  but the subject 
(or caregiver) should wait at least 30 minutes after applying study drug before applying nonmedicated 
emollients ; emollients should not be applied to lesional skin during tr eatment.  The same emollient should be 
used throughout the subject’s participation in the study.  
NOTE :  Any emollient used during the study must be recorded as a concomitant medication.   
5.6.2 Prohibited Medications and Nondrug Therapi[INVESTIGATOR_222172] (Section  4.3).  A list of prohibited medications, emollients and nondrug therapi[INVESTIGATOR_222173] a separate document.   
If a subject chooses to treat scalp with study drug, then medicated shampoos that contain coal tar, salicylic 
acid, or hydrocortisone are prohi bited for use.  
Emollients containing salicylic acid are prohibited.  
 
Tapi[INVESTIGATOR_222143].: DMVT -505-3101 , Amendment 3 
Dermavant Sciences , Inc.  Clinical Study Protocol  
Confidential  Page | 44 6 Study Assessments and Procedures   
Study procedures and assessments are summarized in the Schedule of Assessmen ts and in Section  7.  
Adherence to the study design requirements, including those specified in the Schedule of Assessments ( Table 
1) are essential and required for study conduct.  Protocol waivers or exemptions are not allowed, except for 
immediate safety concerns.  
6.1 Demography, Medical History, and Bas eline Characteristics   
6.1.1 Demographics   
Demographic information collected will include age, sex, race, et hnicity, and Fitzpatrick skin type.  
Information on Fitzpatrick skin type can be found in Appendix 2 . 
6.1.2 Medical History   
Medical history will be collected to ensure subjects are eligible for participation in the study (per inclusion 
Section  4.2 and exclusion Section  4.3 criteria).  
Data collected will include year of AD diagnosis, allerg ic conditions, c ardiovascular (CV) medical history and 
risk factors (including height, weight, blood pressure, medical conditions , and family history of premature CV 
disease), and family history of liver disease.  
As part of the subject’s medical history, a ll systemic (oral and injectable) medications used by [CONTACT_222204] [ADDRESS_266987]’s medical history . 
6.2 Efficacy Assessments   
To minimize inter -observer variability, Investigators and evaluators/raters will be trained on each of the 
required assessments during an Investigator meeting, site initiation visit, and/or utilizing online assessments 
before enrolling subjects at the ir study site.  Only trained evaluators/raters are permitted to perform the 
efficacy assessments.  To the fullest extent possible, the same Investigator (or designated evaluator/rater) will 
perform all efficacy assessments for an individual subject through out the study.  If it is not possible for the 
same evaluator/rater to continue performing assessments, it is recommended that the primary and subsequent 
evaluator/rater both examine and discuss their respective scoring during at least 1  visit.  
6.2.1 Assessments Completed by [CONTACT_10670]   
[IP_ADDRESS]  Validated Investigator Global Assessment of Atopic Dermatitis   
The vIGA -AD™ of disease severity will be assessed at every clinic visit.  The vIGA -AD™ is a global 
assessment of the current state of the disease.  It is a 5 -point morphological assessment of overall disease 
severity  (scalp excluded)  and will be determined according t o the categories described in Table  [ADDRESS_266988] a vIGA -AD™ score of 3 or 4 at Screening and the Baseline 
visit (Day  1).  Eli Lilly and Company developed the vIGA -AD™ scale for use in clinical trials.  
 
 
 
Tapi[INVESTIGATOR_222143].: DMVT -505-3101 , Amendment 3 
Dermavant Sciences , Inc.  Clinical Study Protocol  
Confidential  Page | 46  
 
 
 
   
 
   
 
 
 
 
 
. 
[IP_ADDRESS]  Peak Pruritus -Numeric Rating Scale   
The PP -NRS is a scale used to quickly assess itch/pruritus severit y over a [ADDRESS_266989] 24 h ours.  On clinic 
visit days, the PP -NRS will be assessed in the clinic. For subjects ages 2 to <  12 years , the PP-NRS will be 
completed by [CONTACT_18629] .  For subjects  ages > [ADDRESS_266990].  
An e xample of the PP -NRS is provided in  Appendix 11. 
   
  
 
 
 
 
  
 
  
 
 
 
 

Tapi[INVESTIGATOR_222143].: DMVT -505-3101 , Amendment 3 
Dermavant Sciences , Inc.  Clinical Study Protocol  
Confidential  Page | 47  
 
 
 
 
   
  
  
 
 
   
 
 
 
 
 
6.2.3 Optional Clinical Photography   
Clinical photography may be performed in a subgroup of subjects at selected study sites.  Informed 
consent/assent and photographic release will be required.  The photographs may not be referred to by [CONTACT_222205].  
Photographs will be taken of a repr esentative area of the subject’s disease area at the time points specified in 
the Schedule of Assessments ( Table 1).  Photographs of the selected skin ar ea will be taken in a standardized 
fashion (i.e., same camera, angle, background, distance).   
6.[ADDRESS_266991] signs the informed consent form (ICF) until the 
final visit/contact [CONTACT_1155].  Additional safety information, including the definition of an AE and the 
method s for recording, evaluating, and assessing causality of AEs and the procedures for completing and 
transmitting SAE reports are provided in Section  8. 
6.3.2 Brief Physical Examination   
A brief physical examination will include, at a minimum, assessments of the skin, lungs, CV system, and 
abdomen (liver and spleen).  Assess for chang es in onset of menses (female participants) or sexual activity 
(male or female participants). Determine if there is a need for contraception or barrier use.  Height and weight 
will be measured at Screening only.  Investigators should pay special attention t o clinical signs related to 
previous serious illness.  

Tapi[INVESTIGATOR_222143].: DMVT -505-3101 , Amendment 3 
Dermavant Sciences , Inc.  Clinical Study Protocol  
Confidential  Page | 48 6.3.3 Vital Signs   
Vital signs will be measured before blood collection for clinical laboratory assessments and PK analysis 
(where applicable) and will include measurements of systolic and diastolic blood pressure, pulse rate, and 
body temperature.  Subjects should be in a seated position for at least [ADDRESS_266992] be conducted in accordance with the Study Reference 
Manual or Laboratory Manual and the protocol Schedule of Assessments ( Table 1).  Laboratory requisition 
forms must be completed, and samples must be clearly labeled with the subject number, protocol number, site 
number, and visit da te.  Details for the preparation and shipment of samples will be provided by [CONTACT_222206].  Reference ranges for all safety 
parameters will be provided to the site by [CONTACT_91007].  
A list of clinical laboratory tests and parameters is provided in  Table 4 . 
All laboratory tests with values that are considered clinically significantly abnormal during participation in the 
study should be repeated until th e values return to normal or baseline.  If such values do not return to normal 
within a period judged reasonable by [CONTACT_737], the etiology should be identified, if possible, and the 
Sponsor and Medical Monitor notified.  
Table 4: Laboratory Tests   
Diagnostic Screening Tests  
• HBsAg  
• Hepatitis C antibody  
• Anti-HBc 
• Anti-HBsa • Pregnancy tests: (serum at Screening and urine at other visits  when performed ; 
women of CBP only)b 
• FSH (as needed in women of non -CBP only)  
• At the Investigator’s discretion, subjects may be screened for alcohol and illicit 
drug use.  
Serum Chemistry  
• BUN  
• Creatinine  
• Glucose (fasting not required)  
• Sodium  
• Potassium  
• Chloride  • Total carbon  dioxide  
• Calcium  
• AST  
• ALT  
• Alkaline phosphatase  • Uric acid  
• Total bilirubin (+fractionated if 
required)  
• Total protein  
• Albumin  
Hematology  
• Platelet count  
• RBC count  
• WBC count (absolute)  
• Hemoglobin  
• Hematocrit  • RBC Indices : 
• MCV  
• MCH  
• MCHC  
• Reticulocyte percentage  • WBC  Differential:  
• Neutrophils  
• Lymphocytes  
• Monocytes  
• Eosinophils  
• Basophils  
Urinalysis  
• Specific gravity  
• Microscopic examination (if blood or protein is abnormal  • Dipstick:   pH, Glucose, Protein, 
Blood Ketones  
a. Reflex test: a negative HBsAg and a positive anti-HBc may enroll if there is a positive anti -HBs demonstrating natural immunity  
b. Pregnancy tests should be administered based on CBP, which may change after the start of the study ( e.g. a premenarchal female 
subject experiences menarche or a female su bject ceases to meet the criteria of CBP)  
Tapi[INVESTIGATOR_222143].: DMVT -505-3101 , Amendment 3 
Dermavant Sciences , Inc.  Clinical Study Protocol  
Confidential  Page | 49 ALT  = alanine aminotransferase; Anti -HBc = anti -hepatitis B core antigen; Anti -HBs = anti -hepatitis B surface antigen; 
AST  = aspartate aminotransferase; BUN  = blood urea nitrogen; CBP  = child -bearing potential; FS H = follicle -stimulating hormone; 
HBsAg = hepatitis B surface antigen; MCH  = mean corpuscular hemoglobin; MCHC  = mean corpuscular hemoglobin 
concentration; MCV  = mean corpuscular volume; RBC  = red blood cell(s); WBC  = white blood cell(s).  
6.3.5 Electrocardiogram s  
Single 12 -lead ECGs will be obtained at a subset of sites in a subset of subjects at timepoints indicated in the 
Schedule of Assessments ( Table 1) and Section [ADDRESS_266993], the 
ECG may be repeat ed two additional times over severa l minutes (triplicate in total), to allow further 
evaluation and averaging of interval measurements as necessary.    Abnormal ECGs should be characterized as 
clinically or non -clinically significant by [CONTACT_093].  In the event of a clinically signifi cant change from 
baseline in the ECG for which the etiology cannot be identified, the  Medical Monitor should be contact[INVESTIGATOR_530].  
6.3.6 Local Tolerability Scale   
[IP_ADDRESS]  Investigator -Assessed Local Tolerability Scale   
At each specified study visit, the Investigator (or qualified evaluator) will assess the presence and overall 
degree of irritation at the application sites, ac cording to a 5 -point LTS .  The score will ideally represent an 
“average” across all application sites.  To the fullest extent possible, the same Investigator (or designated 
evaluator) will perform all tolerability assessments for an individual subject thro ughout the study.  If the 
subject is applying study drug to “sensitive areas”, a separate LTS will be used to assess the degree of 
irritation for each of these areas  where study drug is applied .  The sensitive areas that will be assessed are 
face, neck, sk in folds, axilla, inframammary, anal crux, and genitalia.  An example of the Investigator -
assessed LTS is shown in Appendix  15.  The LTS should be completed pre-dose at Baseline and within [ADDRESS_266994] is currently receiving study drug (i.e. 
has applied at least one application in the last 48 hours).  
[IP_ADDRESS]  Subject  (or Caregiver) -Assessed Local Tolerability Scale   
At each specified study visit, the subject or caregiver will separately assess the presence and degree of 
burning/stinging and itching at the application sites, each according to a [ADDRESS_266995] or 
caregiver will not score each sensitive area individually but provide one overall score that will ideally 
represent an “average” across all application sites .  An example of the subject  (or caregiver) -assessed LTS is 
shown in Appendix [ADDRESS_266996] (or caregiver) -assessed LTS should be completed pre -dose at Baseline 
and within [ADDRESS_266997] (or caregiver) -assessed LTS should only completed when the subject is currently receiving study 
drug (i.e. has applied  at least one application in the last 48 hours).  For subjects ages < 12 years, the LTS will 
be completed by [CONTACT_18629].  For subjects ages > [ADDRESS_266998] will be considered an overdose.  
Ingestion of a 30 -gram tube of tapi[INVESTIGATOR_191753], 1% would result in an oral dose of 300  mg. 
Tapi[INVESTIGATOR_222143].: DMVT -505-3101 , Amendment 3 
Dermavant Sciences , Inc.  Clinical Study Protocol  
Confidential  Page | 50 The Sponsor does not recommend specific treatment for an overdose; however, in the event of an overdose, 
the Investigator (or treating physician) should do the following:  
• Contact [CONTACT_191841]  
• Closely monitor the subject for AEs/SAEs and  laboratory abnormalities  
• Provide general symptomatic treatment as necessary  
• Document the quantity of the excess dose as well as the duration of the overdosing.  
• If the Medical Monitor requests a plasma sample for PK analysis, then a blood sample for PK 
should be obtained within [ADDRESS_266999].  
6.5 Pharmacokinetics   
Blood samples for PK analysis of tapi[INVESTIGATOR_222174] a subset of sites in a subset of 
subjects at timepoints indica ted in the Schedule of Assessments ( Table 1) and Section 7.  The actual date and 
time of each blood sample collection will be recorded as well as the date and time of the last dose of study 
drug prior to sample collection.  Collection, processing, storage, and shippi[INVESTIGATOR_222175].  
Concentrations of tapi[INVESTIGATOR_222176] a validated bioanalytical method.  
Raw data will be archived at the bioanalytical site.   
Informed consent/assent for collection of PK sam ples will be required.  
6.[ADDRESS_267000] can only be contact[CONTACT_3012], the following should be assessed or performed:  
• AEs 
• Concomitant Medications  
• Reminder to complete diary  
• Instruction not to discard empty tubes of study drug  
If the subject  has video capabilities, the following items should be assessed or performed:  
• AEs 
• Concomitant Medications  
• vIGA -AD™ assessment (excluding subject’s scalp)  
Tapi[INVESTIGATOR_222143].: DMVT -505-3101 , Amendment 3 
Dermavant Sciences , Inc.  Clinical Study Protocol  
Confidential  Page | 51 • %BSA affected calculation (excluding subject’s scalp)  
• EASI assessment (excluding subject’s scalp)  
• Investigator -assessed LTS 
• Subject (or caregiver) -assessed LTS  
• Application of study drug  by [CONTACT_423]  
• Completion of the PP -NRS  (the subject or caregiver [as applicable] can verbally indicate the 
answer which the study coordinator will document in the sour ce document ) 
• Reminder to complete diary  
• Instruction not to discard empty tubes of study drug  
The reason that assessments cannot be completed during a virtual assessment (i.e., labs, vital signs, physical 
exams, etc.) must be noted (e.g., COVID -19) and the missed assessment s will be recorded as  protocol 
deviation s. 
Tapi[INVESTIGATOR_222143].: DMVT -505-3101 , Amendment 3 
Dermavant Sciences , Inc.  Clinical Study Protocol  
Confidential  Page | 52 7 Timing of Procedures and Assessments   
This section lists the procedures and assessment to be perfo rmed at scheduled timepoints during the study as 
outlined in the Schedule of Assessments ( Table 1).  Information on study procedures and assessments is 
provided in Section  6. 
• Any chan ge in timing or any addition of a timepoint(s) for any planned study assessment must be 
documented in a “Note to File,” which is approved by [CONTACT_222207]; this will NOT c onstitute a protocol 
amendment.  
• The IRB/IEC will be informed of any safety issues that require alteration of the safety monitoring 
or amendment of the ICF.  
NOTE:  Assessments and procedures should be performed  pre-dose on clinic visit days except for LTS  at 
Weeks 1, 2 and 4 . 
7.1 Visit 1; Screening Period (Day -30 to Day -1)  
After the subject has signed the consent/assent form, potential study subjects will undergo Screening 
procedures  and assessments to confirm eligibility to participate in the study.  Screening assessments will 
include the following:  
• Demography recording  
• Fitzpatrick skin type  
• Medical history recording  (including all medications administered up to 30 days prior to scre ening, 
and all systemic [oral and injectable] medications used by [CONTACT_222208] 30 days before Screening)  
• Serum pregnancy test (females of child -bearing potential)  
• Brief physical examination (including height and weight,  body  mass index will be calculated in the 
CRF ) 
• Vital signs measurements  
• Blood sample collection for clinical laboratory tests (serum chemistry, hematology, diagnostic 
tests)  
• Urinalysis  
• AE recording (from the time the ICF is signed)  
• Concomitant medication recording  
• vIGA -AD™ score  (excluding subject’s scalp )  
• %BSA affected calculation (excluding subject’s scalp ) 
• EASI  (excluding subject’s scalp )  
To determine subject eligibility at Screening, a single repeat of tests or procedures may be allowed at the 
discretion of the Investigator.  The Medical Monitor should be consulted if needed.  
Tapi[INVESTIGATOR_222143].: DMVT -505-3101 , Amendment 3 
Dermavant Sciences , Inc.  Clinical Study Protocol  
Confidential  Page | 53 7.2 Visit 2; Baseline (Day  1)  
On Day  1, subjects will be reassessed to confirm c ontinued eligibility to participate in the study.  All subjects 
who continue to meet study eligibility criteria will be randomized to treatment.  
The following additional procedures and assessments will be performed at the Baseline Visit:  
• Changes to medical  history will be recorded  
• Urine pregnancy test (females of child -bearing potential)  
• Brief physical examination  
• Vital signs measurement  
• ECG recording (at a subset of study sites only)  
• Blood sample collection for clinical laboratory tests (serum chemistry, h ematology, diagnostic 
tests)   
NOTE : Blood sample collection for clinical laboratory tests is not required at the Baseline Visit if 
it has been ≤14 days since samples were collected at Screening  and the results of those clinical 
laboratory tests were not cl inically significant .  
• Urinalysis  
NOTE : Urine sample collection for urinalysis is not required at the Baseline Visit if it has been 
≤14 days since samples were collected at Screening and the results of those analyses were not 
clinically significant .  
• Photography of a representative area of the subject’s disease area (at a subse t of study sites  only) 
• AE recording  
• Concomitant medication recording  
• vIGA -AD™ score  (excluding subject’s scalp ) 
• %BSA affected calculation (excluding subject’s scalp ) 
• EASI  (exclud ing subject’s scalp ) 
• Investigator -assessed LTS (pre -dose)  
•  
•  
• PP-NRS  
•  
•  
• Subject  (or caregiver) -assessed LTS  (pre-dose)  
• Dispense diary  (subjects or their caregivers will be instructed on how and when to complete diary)  
• Subject randomized to study treatment  
• Dispense s tudy drug  
• Instruction on how to apply study drug  
• Study drug application under supervision  

Tapi[INVESTIGATOR_222143].: DMVT -505-3101 , Amendment 3 
Dermavant Sciences , Inc.  Clinical Study Protocol  
Confidential  Page | 54 7.3 Visit 3; Week  1 (Day  8 ±2 Days)   
The following procedures and assessments will be performed at Visit 3:  
• Vital signs  
• vIGA -AD™ score  (excluding subject’s scalp ) 
• %BSA affected calculation (excluding subject’s scalp )  
• EASI  (excluding subject’s scalp ) 
•  
•  
• PP-NRS  
•  
•  
• AE recording  
• Concomitant medication recording  
• Collect and review subject diaries for treat ment compliance  
• Dispense subject diaries  
• Collect and dispense study drug  
• Review instructions on how to apply study drug  
• Study drug application under supervision  
• Investigator -assessed LTS  (post -dose)  
• Subject  (or caregiver) -assessed LTS (post -dose)  
7.4 Visit 4;  Week  2 (Day  15 ±2  Days)   
The following procedures and assessments will be performed at Visit 4:  
• Vital signs measurement  
• Photography of a representative area of the subject’s dise ase area (at a subset of study sites  only) 
• AE recording  
• Concomitant medication recording  
• vIGA -AD™ score  (excluding subject’s scalp ) 
• %BSA affected calculation (excluding subject’s scalp )  
• EASI  (excluding subject’s scalp ) 
•  
•  
• PP-NRS  
•  
•  
• Collect and review subject diaries for treatment compliance  

Tapi[INVESTIGATOR_222143].: DMVT -505-3101 , Amendment 3 
Dermavant Sciences , Inc.  Clinical Study Protocol  
Confidential  Page | 55 • Dispense subject diaries  
• Collect and dispense study drug  
• Review instructions on how to apply study dr ug 
• Study drug application under supervision  
• Investigator -assessed LTS  (post -dose)  
• Subject  (or caregiver) -assessed LTS (post -dose)  
7.5 Visit 5; Week  4 (Day  29 ±2  Days)   
The following procedures and assessments will be performed at Visit 5:  
• Urine pregnancy test (females of child -bearing potential)  
• Brief physical examination  
• Vital signs measurement  
• ECG recording (at a subset of study sites only)  
• Blood sample collection for clinical labor atory tests (serum chemistry, hematology, diagnostic 
tests)  
• Urinalysis  
• Blood sample collection for PK analysis (at a subset of study sites only)  
• Photography of a representative area of the subject’s disease area (at a subset of study sites only)  
• AE recordi ng 
• Concomitant medication recording  
• vIGA -AD™ score  (excluding subject’s scalp ) 
• %BSA affected calculation (excluding subject’s scalp )  
• EASI  (excluding subject’s scalp ) 
•  
•  
• PP-NRS  
•  
•  
• Collect and review subject diaries for treatment compliance  
• Dispense subject diaries  
• Collect and dispense study drug  
• Review instructions on how to apply study drug  
• Study drug application under supervision  
• Investigator -assessed LTS  (post -dose)  
• Subject  (or caregiver) -assessed LTS (post -dose)  

Tapi[INVESTIGATOR_222143].: DMVT -505-3101 , Amendment 3 
Dermavant Sciences , Inc.  Clinical Study Protocol  
Confidential  Page | 56 7.6 Visit 6; Week  8 (Day  57 ±2  Days)   
The following procedures and assessments will be performed at Visit 6:  
• Urine pregnancy test (females of child -bearing potential)  
• Brief physical examination  
• Vital signs measurement  
• Blood sample collection for clinical laboratory tests (serum chemistry, hematology, diagnostic 
tests)  
• Urinalysis  
• Blood sample collectio n for PK analysis (at a subset of study sites only)  
• ECG recording (at a subset of study sites only)  
• Photography of a representative area of the subject’s disease area (at a subset of study sites only)  
• vIGA -AD™ score  (excluding subject’s scalp ) 
• %BSA affecte d calculation (excluding subject’s scalp )  
• EASI  (excluding subject’s scalp ) 
•  
•  
• PP-NRS  
•  
•  
• Investigator -assessed LTS  
• Subject  (or caregiver) -assessed LTS  
• AE recording  
• Concomitant medication recording  
• Collect subject diaries  
• Review subject diaries for treatment compliance  
• Collect study drug  
• Enrollment in OL -LTE study (optional)  
7.[ADDRESS_267001] at Weeks  3 (Day  22 ±2  Days) and 6 (Day  43 ±2  Days)   
Subjects or their caregivers will be contact[CONTACT_222209] [ADDRESS_267002] s should be reminded to complete 
their daily diary and bring it with them to the next clinic visit.  
7.8 Follow -Up Visit 7; Week  9 (Day  64 ±2  Days)   
Subjects who complete Visit 6/Week 8 but do not enroll in the OL -LTE study will return to the study site at 
Week  9 to complete Follow -Up assessments as follows:  
• Brief physical examination  

Tapi[INVESTIGATOR_222143].: DMVT -505-3101 , Amendment 3 
Dermavant Sciences , Inc.  Clinical Study Protocol  
Confidential  Page | 57 • Vital signs measurement  
• If needed, blood sample collection for clinical laboratory tests  
• If needed, uri nalysis  
• vIGA -AD™ score  (excluding subject’s scalp ) 
• %BSA affected calculation (excluding subject’s scalp )  
• EASI  (excluding subject’s scalp ) 
•  
•  
• PP-NRS  
•  
•  
• AE recording  
• Concomitant medication recording  
7.9 Early Termination Visit   
Subjects who withdraw early from the study will be asked to return to the study site to comple te Early 
Termination assessments as follows:  
• Urine pregnancy test (females of child -bearing potential)  
• Brief physical examination  
• Vital signs measurement  
• Blood sample collection for clinical laboratory tests  
• Urinalysis  
• ECG recording (at a subset of study sites only)  
• vIGA -AD™  score  (excluding subject’s scalp)  
• %BSA affected calculation (excluding subject’s scalp)   
• EASI  (excluding  subject’s scalp ) 
•  
•  
• PP-NRS  
•  
•  
• Investigator -assessed LTS  
• Subject -assessed LTS  
• AE recording  
• Concomitant medication recording  
• Collect subject diaries  

Tapi[INVESTIGATOR_222143].: DMVT -505-3101 , Amendment 3 
Dermavant Sciences , Inc.  Clinical Study Protocol  
Confidential  Page | 58 • Review subject diaries for treatment compliance  
• Collect study drug  
7.[ADDRESS_267003] an unscheduled visit for AE follow -up, study drug dispensation, make -up for a missed 
visit, or other reason.  The following assessments may be performed:  
• Urine pregnancy test (females of child -bearing potential)  
• Brief physical examination  
• Vital signs measurement  
• Blood sample collection for clinical laboratory tests (serum chemistry, hematology, diagnostic 
tests)  
• Urinalysis  
• ECG recording (at a subset of study sites only)  
• vIGA -AD™ score  (excluding subject’s scalp ) 
• %BSA affected calculation (excluding subject’s scalp )  
• EASI  (excluding subject’s scalp ) 
• Investigator -assessed LTS  
• Subject (or caregiver) -assessed LTS  
• PP-NRS  
• AE recording  
• Concomitant medication recording  
• Dispense and/or collect subject diar ies 
• Review subject diaries for treatment compliance  
• Dispense and/or collect study drug  
• Review instructions on how to apply study drug  
7.[ADDRESS_267004] has completed the Week  9 Follow -up Visit which 
is 1 week after the end of treatment (if subject does not enroll  in the OL -LTE study) OR the last active subject 
has completed the 8  weeks of treatment in this study (if subject is  eligible and enrolls in the OL -LTE study).  
Tapi[INVESTIGATOR_222143].: DMVT -505-3101 , Amendment 3 
Dermavant Sciences , Inc.  Clinical Study Protocol  
Confidential  Page | [ADDRESS_267005]   
The Investigator or site staff is responsible for detecting, documenting, and reporting events that meet the 
definition of an AE, SAE, or AESIs.  At each visit/contact, subjects should be questioned in  a general way so 
as not to introduce bias in detecting AEs and/or SAEs.  Open -ended and non -leading verbal questioning of the 
subject is the preferred method to inquire about AE occurrence.  
Investigators are not obligated to actively seek AEs or SAEs in f ormer study subjects.  However, if the 
Investigator learns of any SAE, including a death, at any time after a subject has been discharged from the 
study, and he/she considers the event reasonably related to the study drug or study participation, the 
Invest igator should promptly notify the Sponsor.  
A narrative will be written and included in the Clinical Study Report  for all SAEs  and AESIs, and for all AEs 
that lead to study discontinuation.  
8.1.[ADDRESS_267006].  
An AE can therefore be any  unfavorable and unintended sign (including an abnormal laboratory finding), 
symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product.  
Events meeting the definition of an AE include:  
• Any abnormal laboratory test re sults (hematology, clinical chemistry) or other safety assessments 
(e.g., vital signs measurements), including those that worsen from Baseline, and felt to be 
clinically significant in the medical and scientific judgment of the Investigator  
• Exacerbation of  a chronic or intermittent pre -existing condition (e.g., plaque psoriasis) including 
either an increase in frequency and/or intensity of the condition  
• For skin -related AEs, it should be noted whether or not the event is in the area of active application 
of study drug, and/or if spreading beyond the application site.  
• New conditions detected or diagnosed after study drug administration even though it may have 
been present prior to the start of the study  
• Signs, symptoms, or the clinical sequelae of a suspected  interaction  
• Signs, symptoms, or the clinical sequelae of a suspected overdose of either study drug or a 
concomitant medication (overdose per se will not be reported as an AE/SAE)  
• "Lack of efficacy" or "failure of expected pharmacological action" per se wi ll not be reported as an 
AE or SAE.  Such instances will be captured in the efficacy assessments.  However, the signs, 
symptoms, and/or clinical sequelae resulting from lack of efficacy will be reported as AE or SAE 
if they fulfill the definition of an AE or SAE.  
Events that do not  meet the definition of an AE include:  
• Any clinically significant abnormal laboratory findings or other abnormal safety assessments that 
are associated with the underlying disease, unless judged by [CONTACT_222210]’s condition  
Tapi[INVESTIGATOR_222143].: DMVT -505-3101 , Amendment 3 
Dermavant Sciences , Inc.  Clinical Study Protocol  
Confidential  Page | 60 • The disease/disorder being studied or expected progression, signs, or symptoms of the 
disease/disorder being studied, unless more severe than expected for the subject’s condition  
• Medical or surgical procedure (e .g., endoscopy, appendectomy); the condition that leads to the 
procedure is an AE  
• Situations where an untoward medical occurrence did not occur (social and/or convenience 
admission to a hospi[INVESTIGATOR_307])  
• Anticipated day -to-day fluctuations of pre -existing disease( s) or condition(s) present or detected at 
the start of the study that do not worsen  
8.1.2 Definition of Serious Adverse Event   
If an event is not an AE per Section  8.1.1 , then it cannot be an SAE even if serious conditions are met (e.g., 
hospi[INVESTIGATOR_1080]/symptoms of the disease under study, death due to progression of disease, etc.).  
An SAE is any untoward medical occurrence that, at any dose:  
• Results in death  
• Is life -threatening  
− The term “life threatening” refers to an event in which the subject was at risk of death at the 
time of the event.  It does not refer to an ev ent, which hypothetically might have caused death, 
if it were more severe.  
• Requires hospi[INVESTIGATOR_1081]  
− In general, signifies that the subject has been detained (usually involving at least an overnight 
stay) at the h ospi[INVESTIGATOR_22771]/or treatment that would not have 
been appropriate in the physician’s office or outpatient setting.  Complications that occur 
during hospi[INVESTIGATOR_1084].  If a complication prolongs hospi[INVESTIGATOR_222177], the event is serious.  When in doubt as to whether “hospi[INVESTIGATOR_059]” occurred or 
was necessary, the AE should be considered serious.  
− Hospi[INVESTIGATOR_5187] a pre -existing condition that did not worsen from 
Baseline is not considered an AE.  
• Results in disability/incapacity:  a substantial disruption of a person’s ability to conduct normal life 
functions.  
− This definition is not intended to include experiences of relatively minor medical significance 
such as uncomplicated headache, nausea, vomiting, diarrhea, influenza, and accidental trauma 
(e.g., sprained ankle) which may interfere or prevent everyday life functions but do not 
constitute a substantial disruption.  
• Results in a congenital anomaly/birth defect  
Medical or scientific judgment should be exercised in deciding whether reporting is appropriate in other 
situations, such as important medical events that may not be immediately life -threatening or result in death or 
hospi[INVESTIGATOR_222178].  These should also be considered serious.  Examples of 
such events are invasive or malignant cancers, intensive treatment in an eme rgency room or at home for 
Tapi[INVESTIGATOR_222143].: DMVT -505-3101 , Amendment 3 
Dermavant Sciences , Inc.  Clinical Study Protocol  
Confidential  Page | [ADDRESS_267007] be collected for each of these 
AESIs:  
Contact [CONTACT_222211], duration, size, associated symptoms (itching, burning, pain), severity 
(mild, moderate, severe), time to onset, and photograph the affected site (if possible).  If the subject or 
caregiver contacts the study site to repor t significant skin irritation at or near the site of study drug application 
between study visits, the subject should be brought in for an unscheduled visit, if possible.  
Headache  
The study site should collect duration, severity (mild, moderate, severe), ti me to onset, and location (e.g., 
frontal, temporal, occipi[INVESTIGATOR_307], diffuse).  
Follicular Event  
The study site should collect the location, duration, size, associated signs and symptoms (itching, burning, 
pain, erythema ), severity (mild, moderate, severe), describe morphology  [scale (keratotic/cornified) or no 
scale (non -keratotic/non -cornified)] , time to onset, and photograph the affected site (if possible).   Additional 
information regarding management of folliculitis is provided in Section [IP_ADDRESS].4 . 
In particular, the term ‘folliculitis’ may not correctly  describe the  morphology of the observed local follicular 
events as these appear to be more consistent with a keratoses pi[INVESTIGATOR_22785] -like fo llicular based papule. Tapi[INVESTIGATOR_222179], including involucrin, hornerin, and filaggrin and increased 
cornification at, and subsequent mechanical occlusion of, the follicular ostia has been suggested to be a 
potentiall y on target mechanism by [CONTACT_222212][INVESTIGATOR_191753]. Additional morphologic description will help to more fully and appropriately characterize 
these follicular events.      
Possible descriptors  include,  but are not limited to : 
• Folliculitis  
− Non-inflammatory  
− Inflammatory  
• Milia  
− Non-inflammatory  
− Inflammatory  
• Keratos is pi[INVESTIGATOR_222180].: DMVT -505-3101 , Amendment 3 
Dermavant Sciences , Inc.  Clinical Study Protocol  
Confidential  Page | 62 − Non-inflammatory  
− Inflammatory  
Additional AESIs may be identified during the evaluation of safety data for the Clinical Study Report.  
8.2 Classification of Adverse Events   
8.2.1 Assigning Severity Rating for Adverse Events   
[IP_ADDRESS]  Criteria for D etermining A dverse Event Severity   
The Investigator will make an assessment of the severity of each AE and SAE according to the National 
Cancer Institute CTCAE, v. 5.0,  2017.  For  terms not specified with the CTCAE, the criteria in Table 5 should 
be used to determine the grade severity.  
Table  5: Criteria for Determining the Grade/Severity of Adverse Event Terms Not Specified by 
[CONTACT_222213]  
1 Mild; asymptomatic or mild symptoms, clinical or diagnostic observations only; intervention not indicated  
2 Moderate; minimal, local, or noninvasive intervention indicated; limiting age -appropriate instrumental activities of 
daily livinga 
3 Severe or medically significant but not immediately life -threatening; hospi[INVESTIGATOR_48622]; disabling; limiting  self-care activities of daily livingb 
4 Life threatening consequences; urgent intervention indicated  
5 Death related to adverse event  
a. Instrumental activities of daily living refer to preparing meals, shoppi[INVESTIGATOR_3112], using the tele phone, managing 
money, etc.  
b. Self -care activities of daily living refer to bathing, dressing and undressing, feeding self, using the toilet, taking medications , and 
not bedridden.  
CTCAE  = Common Terminology Criteria for Adverse Events.  
 
AE severity should be recorded in the appropriate section of the AE CRF  and in the subject’s source 
documents.  
[IP_ADDRESS]  Toxicity Management Criteria   
[IP_ADDRESS].[ADDRESS_267008] study 
withdrawal/ early termination  evaluations completed.  
[IP_ADDRESS].2  Grade 3  Adverse Event   
Subjects who develop a Grade 3  AE should be managed as follows:  
• If the Investig ator has compelling evidence that the Grade [ADDRESS_267009], then dosing may continue after discussion with the Medical Monitor.  
• Subjects who develop a Grade [ADDRESS_267010] withd rawal study evaluations completed.  
Tapi[INVESTIGATOR_222143].: DMVT -505-3101 , Amendment 3 
Dermavant Sciences , Inc.  Clinical Study Protocol  
Confidential  Page | 63 [IP_ADDRESS].[ADDRESS_267011] withdrawal study evaluations 
completed.  
[IP_ADDRESS].[ADDRESS_267012] not required nor resulted in the need for intervention, s everal approaches 
can be employed to manage those patients with folliculitis who may be symptomatic including temporary 
interruption of study drug  use at sites of folliculitis and/or the local application to affected areas of topi[INVESTIGATOR_222181] 12% lactic acid lotion or 5-10% urea cream s or lotion s. 
[IP_ADDRESS].5  Other Management Criteria:   
The Medical Monitor should be notified if any of the following occur:  
• Severe signs or symptoms, or significant changes in any of the safety assessments, that put the 
safety of the subject at risk (e.g., laboratory tests or vital signs, etc.) as judged by [CONTACT_737].  
8.2.2 Assigning Causal Relationship to Study Drug   
The Principal Investigator [INVESTIGATOR_11637] -Investigator  is to make the causality assessment.  The reasonable pos sibility 
of the relationship of an AE to study drug is to be assessed with careful medical consideration at the time of 
evaluation of an AE.  The following definitions are to be used for the relationship of the AE to study drug:  
• Related :  A clinical event,  including laboratory test abnormality, with a temporal relationship to 
study drug administration that makes a causal relationship plausible, unlikely attributed to 
concurrent disease or other drugs or chemicals, and that follows a clinically reasonable re sponse 
on re -administration (rechallenge) or withdrawal (dechallenge), although information on drug 
withdrawal may be lacking or unclear.  
• Not related :  A clinical event, including laboratory test abnormality, with a temporal relationship 
to study drug admi nistration that makes a causal relationship improbable and/or in which other 
drugs, chemicals, or underlying disease provide a plausible explanation.  
Any AEs /SAEs assessed as related to study participation (e.g., protocol -mandated procedures, invasive tests, 
or change in existing therapy) or related to study drug will be recorded from the time a subject consented to 
participate in the study up to and including any follow -up contact.  
All AEs, whether related to study drug or not, must be fully and comple tely documented on the AE page of 
the CRF and in the subject’s clinical record.  In the event a subject is withdrawn from the study because of an 
AE, the primary reason for withdrawal (i.e., due to an AE) must be recorded on the CRF as such.  
Tapi[INVESTIGATOR_222143].: DMVT -505-3101 , Amendment 3 
Dermavant Sciences , Inc.  Clinical Study Protocol  
Confidential  Page | 64 8.3 Time Period an d Frequency for Event Assessment and Follow -Up  
8.3.1 Adverse Event Reporting   
All AEs will be collected fro m the time of signed informed consent until the final visit.  
Any AEs assessed as related to study participation (e.g., protocol -mandated procedures, invasive tests, or 
change in existing therapy) will be collected from the time a subject consented to parti cipate in the study up to 
and including any follow -up contact.  
All SAEs will be recorded in the CRF and reported to the Sponsor within 24  hours via email or phone ( refer 
to Medical Monitor / Sponsor Information Page  for contact [CONTACT_3031]) (see Section  8.4). 
8.3.2 Follow -Up of Adverse Events   
After the initial AE/SAE report, the Invest igator is required to proactively follow each subject at subsequent 
visits/contacts.  All SAEs and nonserious AEs will be followed until resolution, until the condition stabilizes, 
until the event is otherwise explained, or if the subject is lost to follow -up. 
The Investigator will assess the outcome of each AE using the following criteria:  
• Recovered/Resolved :  The event has improved or subject recuperated.  
• Recovered/Resolved with sequelae :  The subject has recuperated but retained pathological 
conditions r esulting from the prior disease or injury.  
• Recovering/Resolving :  The event is improving.  
• Not recovered/Not resolved :  The event has not improved or subject recuperated.  
• Unknown :  The outcome of the event is not known, not observed, not recorded, or refuse d. 
• Fatal :  Termination of life as an outcome of the AE.  
8.4 Reporting Procedures   
8.4.1 Serious Adverse Event Reporting   
When an Investigator determines that an AE meets the protocol definition of an SAE during the study, he/she 
must notify the Sponsor using an SAE Report Form within 24  hours of the study site personnel’s 
knowledge of the event , regardless of the In vestigator assessment of the relationship of the event to study 
drug.  Relevant information will be entered on the AE page and on all other applicable pages of the CRF; 
source documentation should not be sent with the SAE Report Form unless requested.  
Follow-up information received on SAEs should be emailed or faxed to the Sponsor within 1  business day of 
receipt (refer to  Medical Monitor/ Sponsor Information Page  for contact [CONTACT_3031]).  This information 
should be included on a follow -up SAE form and filed with the original SAE information.  
All SAEs will be followed until resolution, until the condition stabilizes, until the event is otherwise 
explained, or until the subject is lost to follow -up. 
The completed SAE Report form should be submitted via email  or fax to the SAE Reporting Contact [CONTACT_222214]/ Sponsor Information Page  of this protocol.  
Do not delay reporting a suspected SAE in order to obtain additional information.  Any additional 
information, if collected, can be reported as a follow -up to the initial report.  
Tapi[INVESTIGATOR_222143].: DMVT -505-3101 , Amendment 3 
Dermavant Sciences , Inc.  Clinical Study Protocol  
Confidential  Page | 65 8.4.2 Regulatory Reporting Requirements for Serious Adverse Events   
Prompt notification by [CONTACT_222215] (even f or non -interventional post -marketing 
studies) is essential so that legal obligations and ethical responsibilities towards the safety of subjects and the 
safety of a product under clinical investigation are met.  
The Sponsor has a legal responsibility to not ify both the local regulatory authority and other regulatory 
agencies about the safety of a product under clinical investigation.  The Sponsor will comply with 
country -specific regulatory requirements relating to safety reporting to the regulatory authorit y, IRB/IEC, and 
Investigators.  
Investigator safety reports are prepared for suspected unexpected serious adverse reactions according to local 
regulatory requirements and are forwarded to Investigators as necessary.  
An Investigator who receives an Investigator safety report describing a SAE(s) or other specific safety 
information (e.g., summary or listing of SAEs) from the Sponsor will file it with the Investigator’s Brochure 
and will notify the IRB/IEC, if appropriate, according to local requiremen ts. 
8.[ADDRESS_267013] information can be found on the  Medical 
Monitor / Sponsor Information Page  of this protocol, within [ADDRESS_267014] will also be followed to determine the outcome of the pregnancy.  Information on the status of the 
mother and child will be forwarded to the Sponsor.  Generally, follow -up will be no lo nger than 6  to 8 weeks 
following the estimated delivery date.  Any premature termination of the pregnancy will be reported.  
Any SAE occurring in association with a pregnancy brought to the Investigator’s attention after the subject 
has completed the study and considered by [CONTACT_222216]’s representative.  
The Investigator must attempt to collect pregnancy information on any female partners of male study subjects 
who become pregnant while the subject is enrolled in the study.  Pregnancy information must be reported to 
the Sponsor or the Sponsor’s representative as described above.  The partner will also be followed to 
determine the outcome of the pregnancy.  Inform ation on the status of the mother and child will be forwarded 
to Sponsor or the Sponsor’s representative.  Generally, follow -up will be no longer than 6  to 8 weeks 
following the estimated delivery date.  Any premature termination of the pregnancy will be r eported on the 
Pregnancy Report Form. 
Tapi[INVESTIGATOR_222143].: DMVT -505-3101 , Amendment 3 
Dermavant Sciences , Inc.  Clinical Study Protocol  
Confidential  Page | [ADDRESS_267015] initials will not be collected or tra nsmitted to the Sponsor.  
Tapi[INVESTIGATOR_222143].: DMVT -505-3101 , Amendment 3 
Dermavant Sciences , Inc.  Clinical Study Protocol  
Confidential  Page | 67 10 Statistical Considerations and Data Analyses   
This study will evaluate the efficacy and safety of tapi[INVESTIGATOR_191753], 1% compared with vehicle control cream 
in adults and children with AD.  
10.1 General Considerations   
All study data will be summarized by [CONTACT_2070].  Categorical variables will 
be reported using frequency and percentage (e.g., gender, race).  Continuous variables will be reported using 
number of subjects, mean, standard deviation (SD), median, minimum, and maximum.  All efficacy and 
safety data will be listed by [CONTACT_1130].  
10.2 Determination of Sam ple Size   
It is estimated that the proportion of subjects who will achieve a vIGA -AD™ score of [ADDRESS_267016] a 2 -
grade reduction from Baseline  at Week 8 will be 45% for subjects receiving tapi[INVESTIGATOR_222182] 25% for 
subjects receiving vehicle control, based upon the Phase 2 results.  With 400 subjects randomized in a 2:1 
ratio (2 67 subjects receiving tapi[INVESTIGATOR_191752], and 1 33 subjects receiving vehicle  control), this will provide 97.2% 
power  for statistical significance (2 -sided p < 0.05).  The power is calculated from a Fisher Exact sample size 
calculation.  It is assumed that 15% of the subjects receiving tapi[INVESTIGATOR_222183] -up by 8 weeks  
compared with 30% of the subjects receiving vehicle control.  These subjects will be included in the primary 
analysis using the multiple imputation method.  
10.[ADDRESS_267017] 1  application of study drug will be included in the Safety 
population.  Subjects will be analyzed as treated.  
10.3.2  Intent -To-Treat   
All randomized subjects will be included in the Intent -to-treat (ITT) population.  Subjects will be analyzed as 
randomized.  
10.3.[ADDRESS_267018] the interpretation of the primary efficacy endpoint will be included in the  Per Protocol (PP) 
population.    
10.3.[ADDRESS_267019] evaluable concentration -time data for analysis will 
be included in the PK population.  A sample that is be low the quantification limit of the assay is considered 
evaluable.  
10.4 Planned Analyses   
All efficacy and safety measures over the course of the study will be presented.  Details of planned analyses , 
including the handling of subjects whose visits are impacted by [CONTACT_25963] -19 pandemic,  will be described in 
the Statistical Analysis Plan.  
Tapi[INVESTIGATOR_222143].: DMVT -505-3101 , Amendment 3 
Dermavant Sciences , Inc.  Clinical Study Protocol  
Confidential  Page | 68 10.4.1  Disposition and Demographics   
Demographic and baseline characteristics as well as medical history will be summarized using the ITT 
population, including frequency and percentages for categorical variables and mean, SD, median, minimum, 
and maximum for continuous variables.  
The numbers of subjects in the different analysis populations will be summarized by [CONTACT_1570], 
including overall categories.  
10.4.2  Efficacy Analyses   
All efficacy analyses will be bas ed on the ITT population and will be repeated for the PP  population only for 
the primary and secondary efficacy endpoints as supportive analysis.  
[IP_ADDRESS]   Primary Endpoint Analyses    
The primary estimand of interest is the composite estimand in a patient population offered treatment with 
tapi[INVESTIGATOR_191753], 1% as compared to vehicle  (see Table 6).  Interest is focused on the treatment effect 
measured by [CONTACT_222217] 8. The primary efficacy endpoint for treatment effectiveness 
is proportion of subjects who a chieve vIGA -AD™ score of clear (0) or almost clear (1) and at least a [ADDRESS_267020] on efficacy evaluations prior to 
Week 8 will be considered treatment failure as of the start of the intercurrent event.   
Table 6 Primary Estimand Attributes   
Estimand Attribute  Description  
Treatment  tapi[INVESTIGATOR_191753], 1% compared to vehicle  
Population  Intent -to-treat 
Variable of interest  Proportion of subjects who achieve vIGA -AD™ score of clear 
(0) or almost clear (1) and at least a [ADDRESS_267021] on efficacy evaluations 
prior to Week 8 will  be considered treatment failure.  
Investigator a ssessments will only include data collected at in -
person visits.  
Summary measure  Ratio of response rates at Week 8  
The primary efficacy endpoint will be analyzed using a Cochran –Mantel –Haenszel (CMH) test stratified by 
[CONTACT_222218]™ score at Baseline (vIGA AD™ scores of 3 or 4) and by [CONTACT_551] (2 -6 years, 7 -11 years, 12 -17 
years, 18 years and above). Handling of missing values is described in Section 10.6. 
[IP_ADDRESS]  Secondary and Exploratory Efficacy Endpoint Analyses   
The secondary efficacy endpoints are as follows:  
• Proportion of subjects with ≥  75% impr ovement in EASI from Baseline at Week 8  
• Mean change in %BSA affected from Baseline at Week 8  
• Proportion of subjects with ≥ 90% improvement in EASI from Baseline at Week 8  
Tapi[INVESTIGATOR_222143].: DMVT -505-3101 , Amendment 3 
Dermavant Sciences , Inc.  Clinical Study Protocol  
Confidential  Page | 69 • Proportion of subjects > 12 years old with a Baseline PP -NRS score > 4 who achieve ≥ 4-point 
reduction in the PP -NRS from Baseline at Week 8  
Exploratory efficacy endpoints are as follows:  
•   
   
 
  
   
  
  
  
  
  
   
   
    
 
    
 
   
 
The same methods as discussed for the pri mary analys is of the primary endpoint will be used to analyze all 
dichotomized secondary endpoints.  The secondary efficacy endpoints will be tested sequentially in the order 
listed.  Testing will stop if non -significance (2 -sided p ≥  0.05) is observed.  
Post-baseline weekly PP -NRS scores will be an average of [ADDRESS_267022] for proportions, and analysis of covariance 
(ANCOVA) model for continuous variables.  CMH tests will be stratified by [CONTACT_222200] -AD™  score  and 
age group , and ANCOVA models will include vIGA -AD™  score and age  group as categorical covariates and 
Baseline as a continuous covariate . 
All endpoints will be summarized descriptively as follows:  continuous data will include the mean, SD, 
minimum, maximum, median, and number of observations; descriptive summary statistics for categorical data 
will include frequency counts and percentages.  
10.4.[ADDRESS_267023] and treatment 
and summarized by [CONTACT_3148].  No formal statistical comparisons will  be made for safety data.  

Tapi[INVESTIGATOR_222143].: DMVT -505-3101 , Amendment 3 
Dermavant Sciences , Inc.  Clinical Study Protocol  
Confidential  Page | [ADDRESS_267024] complete data at all visits .  The primary method of handling of missing 
data will utilize Multiple Imputations (MI).  For sensitivity analysis of the primary and secondary endpoints, 
Last Observation Carried Forward (LOCF) and Treatment Failure (TF) will be imputed for missing data.  
For t he MI model, 100  imputations will be generated using PROC MI of SAS.  Fully Conditional 
Specification model using the regression method will be used with the response (e.g., vIGA -AD™  score) at 
prior post -Baseline visits, Baseline strata, and treatment group as covariates . The ROUND and MINIMUM 
options will be utilized to ensure imputed values are non -negative integers.  The results of the 100  analyses 
will be transformed into a normal  statistic and combined into a single analysis using PROC MIANALYZE . 
Additional sensitivity analyses of the primary endpoint will be performed  via tippi[INVESTIGATOR_18275] . 
Tapi[INVESTIGATOR_222143].: DMVT -505-3101 , Amendment 3 
Dermavant Sciences , Inc.  Clinical Study Protocol  
Confidential  Page | 72 11 Responsibilities   
11.1 Investigator Responsibilities   
11.1.1  Good Clinical Practice   
The Investigator will ensure that thi s study is conducted in accordance with the principles of the “Declaration 
of Helsinki” (as amended in Edinburgh, Tokyo, Venice, Hong Kong, and South Africa), International 
Conference on Harmonization guidelines, or with the laws and regulations of the cou ntry in which the 
research is conducted, whichever affords the greater protection to the study subject.  For studies conducted 
under a [LOCATION_002] Investigational New Drug Application, the Investigator will ensure that the basic 
principles of “Good Clini cal Practice,” as outlined in 21  Code of Federal Regulations (CFR) 312, subpart D, 
“Responsibilities of Sponsors and Investigators,” 21  CFR, part 50, 1998, and 21  CFR, part 56, 1998, are 
adhered to.  These standards are consistent with the requirements of the European Community Directive 
2001/20/EC.  
Since this is a “covered” clinical trial, the Investigator will ensure that 21  CFR, Part 54, 1998, is adhered to; a 
“covered” clinical trial is any “study of a drug or device in humans submitted in a marketing a pplication or 
reclassification petition subject to this part that the applicant or Food and Drug Administration relies on to 
establish that the product is effective (including studies that show equivalence to an effective product) or that 
make a significan t contribution to the demonstration of safety.”  This requires that Investigators and all sub -
Investigators must provide documentation of their financial interest or arrangements with the Sponsor, or 
proprietary interests in the drug being studied.  This d ocumentation must be provided before participation of 
the Investigator and any sub -Investigator.  The Investigator and sub -Investigator agree to notify the Sponsor 
of any change reportable interests during the study and for [ADDRESS_267025]/Independent Ethics Committee Approval   
This protocol and any accompanying material to be provided to the subject (such as advertisements, subject 
information sheets, or descriptions of the study used to obtain informed consent) will be submitted by [CONTACT_222219].  Approval from the IRB or IEC must be 
obtained before starting the study and should be documented in a letter to the Investigator specifying the 
protocol number, protocol version, protocol date, documents reviewed, and date on which the committee met 
and granted the approval.  
Any modifications made to the protocol after receipt of IRB or IEC approval must also be submitted to the 
IRB or IEC for approval before implementation.  
11.1.3  Informed Consent/Assent   
The Investigator is responsible for obtaining written informed consent/assent from each individual 
participating in this study after adequate explanation of the aims, methods, objectives, and potential hazar ds of 
the study and before undertaking any study -related procedures.  The Investigator must utilize an IRB - or IEC -
approved consent form for documenting written informed consent.  Each informed consent/assent will be 
appropriately signed and dated by [CONTACT_941] s ubject or the subject’s legally authorized representative and the person 
obtaining consent.  
Tapi[INVESTIGATOR_222143].: DMVT -505-3101 , Amendment 3 
Dermavant Sciences , Inc.  Clinical Study Protocol  
Confidential  Page | [ADDRESS_267026] assure that subjects’ anonymity will be strictly  maintained and that their identities are 
protected from unauthorized parties.  Only subject number, date of birth, and an identification code (i.e., not 
names) should be recorded on any form or biological sample submitted to the Sponsor, IRB or IEC, or 
laboratory.  The Investigator must keep a screening log showing codes, names, and addresses for all subjects 
screened and for all subjects enrolled in the trial.  
The Investigator agrees that all information received from the Sponsor, including but not limite d to the 
Investigator Brochure, this protocol, CRFs, the investigational new drug, and any other study information, 
remain the sole and exclusive property of the Sponsor during the conduct of the study and thereafter.  This 
information is not to be disclos ed to any third party (except employees or agents directly involved in the 
conduct of the study or as required by [CONTACT_2371]) without prior written consent from the Sponsor.  The Investigator 
further agrees to take all reasonable precautions to prevent the disclo sure by [CONTACT_222220].  
11.1.[ADDRESS_267027] 
the following 2  categories: (1) Investigator’s study file, and (2) s ubject clinical source documents.  
The Investigator’s study file will contain the protocol/amendments, CRF and query forms, IRB or IEC and 
governmental approval with correspondence, informed consent, drug records, staff curriculum vitae and 
authorization fo rms, and other appropriate documents and correspondence.  
The required source data should include at least the following information for each subject:  
• Subject identification (name, date of birth, gender)  
• Documentation that subject meets eligibility criteria , i.e., history, physical examination, and 
confirmation of diagnosis (to support inclusion and exclusion criteria)  
• Participation in trial (including trial number)  
• Trial discussed and date of informed consent  
• Dates of all visits  
• Documentation that protocol -specific procedures were performed  
• Results of efficacy parameters, as required by [CONTACT_760]  
• Start and end dates (including dose regimen) of trial medication (preferably drug dispensing and 
return should be documented as well)  
• Record of all adverse event s and other safety parameters (start and end date, and preferably 
including causality and intensity)  
• Concomitant medication (including start and end dates, dose if relevant; dose changes should be 
recorded ) 
• Date of trial completion and reason for early dis continuation, if applicable  
All clinical study documents must be retained by [CONTACT_31201] [ADDRESS_267028] approval 
of a marketing application in an ICH region (i.e., [LOCATION_002], Europe, or Japan) and until there are no 
Tapi[INVESTIGATOR_222143].: DMVT -505-3101 , Amendment 3 
Dermavant Sciences , Inc.  Clinical Study Protocol  
Confidential  Page | 74 pending or contemplated marketing applications in an ICH region; or, if no application is filed or if the 
application is not approved for such indication, until [ADDRESS_267029] is withdrawn from the study because of a treat ment -limiting AE, 
thorough efforts should be made to clearly document the outcome.  
11.1.7  Drug Accountability   
The Investigator or designee (i.e., pharmacist) is responsible for ensuring  adequate accountability of all used 
and unused investigational medicinal product.  This includes acknowledgment of receipt of each shipment of 
study product (quantity and condition), subject dispensing records, and returned or destroyed study product.  
Dispensing records will document quantities received from the Sponsor and quantities dispensed to subjects, 
including kit or lot number, date dispensed, subject identifier number, and the initials of the person dispensing 
the medication.  
At study initiation,  the monitor will evaluate the site’s procedure for investigational medicinal product 
disposal/destruction in order to ensure that it complies with the Sponsor requirements.  At the end of the 
study, following final drug inventory reconciliation by [CONTACT_222221], the study site will dispose of and/or 
destroy all unused investigational medicinal product supplies, including empty containers, according to these 
procedures.  If the site cannot meet the Sponsor’s requirements for disposal, arrangements will be mad e 
between the site and the Sponsor or its representative for destruction or return of unused investigational 
medicinal product supplies.  
All drug supplies and associated documentation will be periodically reviewed and verified by [CONTACT_222222].  
11.1.8  Inspections   
The Investigator should understand that source documents for this trial should be made available to 
appropriately qualified personnel from the S ponsor or its representatives, to IRBs or IECs, or to regulatory 
authority or health authority inspectors.  
Tapi[INVESTIGATOR_222143].: DMVT -505-3101 , Amendment 3 
Dermavant Sciences , Inc.  Clinical Study Protocol  
Confidential  Page | [ADDRESS_267030] be obtained before changes can be implemented.  
11.2.2  Study Report and Publications   
A clinical study report will be prepared and  provided to the regulatory agency(ies).  The Sponsor will ensure 
that the report meets the standards set out in the ICH Guideline for Structure and Content of Clinical Study 
Reports (ICH E3).  Note that an abbreviated report may be prepared in certain cas es. 
After conclusion of the study and without prior written approval from Dermavant Sciences , Inc. , Investigators 
in this study may communicate, orally present, or publish in scientific journals or other scholarly media only 
after the following conditions have been met:  
• The results of the study in their entirety have been publicly disclosed by [CONTACT_222223] , Inc. , in an abstract, manuscript, or presentation form; OR  
• The study has been completed at all study sites for at least 5  years. 
No such communication, presentation, or publication will include Dermavant Sciences , Inc.  confidential 
information (see Section  11.1.4 ). 
The I nvestigator will submit any proposed publication or presentation along with the respective scientific 
journal or presentation forum at least [ADDRESS_267031] to delete references to its confidential 
information (other than the study results) in any paper or presentation and agrees to withhold publication or 
presentation for an additional 60  days in order to obtain patent protection if deemed nece ssary.  
11.2.3  Posting of Information on Publicly Available Clinical Trial Registers   
Study information from this protocol will be posted on publicly available clinical trial registers as  required by 
[CONTACT_5279].  Results will be posted as required.  
11.3 Joint Investigator/Sponsor Responsibilities   
11.3.[ADDRESS_267032] access to the 
Investigator’s source documentation in order to verify the data recorded in the CRFs for consi stency.  
The monitor is responsible for routine review of the CRFs at regular intervals throughout the study to verify 
adherence to the protocol and the completeness, consistency, and accuracy of the data being entered on them.  
The monitor should have acce ss to any subject records needed to verify the entries on the CRFs.  The 
Investigator agrees to cooperate with the monitor to ensure that any problems detected in the course of these 
monitoring visits are resolved.  
Tapi[INVESTIGATOR_222143].: DMVT -505-3101 , Amendment 3 
Dermavant Sciences , Inc.  Clinical Study Protocol  
Confidential  Page | [ADDRESS_267033] of any 
inspection or audit.  
11.3.3  Study Discontinuation   
The Sponsor reserves the right to terminate the study at any time.  Should this be n ecessary, the Sponsor will 
arrange discontinuation procedures and notify the appropriate regulatory authority(ies), IRBs, and IECs.  In 
terminating the study, the Sponsor and the Investigator will assure that adequate consideration is given to the 
protecti on of the subjects’  interests.  
 
 
 
 
 
 
 
 
Tapi[INVESTIGATOR_222143].: DMVT -505-3101 , Amendment 3 
Dermavant Sciences , Inc.  Clinical Study Protocol  
Confidential  Page | 78 13 Appendices   
Appendix 1. Hanifin and Rajka Criteria for Atopic Dermatitis Diagnosis   
Major Criteria (must have at  least three)  
• Pruritus  
• Typi[INVESTIGATOR_22784]:  
− Adults: flexural lichenification or linearity  
− Children and infants: involvement of facial and extensor surfaces  
• Chronic or chronically relapsing dermatitis  
• Personal or family history of atopy (ast hma, allergic rhinitis, atopic dermatitis)  
Minor Criteria (must have at least three)  
• Xerosis  
• Ichthyosis/keratosis pi[INVESTIGATOR_22785]/palmar hyperlinearity  
• Immediate (Type 1) skin test reactivity  
• Elevated serum IgE  
• Early age at onset  
• Tendency to skin infections (Staph ylococcus aureus, herpes simplex)/impaired cellular immunity  
• Tendency to nonspecific hand/foot dermatitis  
• Nipple eczema  
• Cheilitis  
• Recurrent conjunctivitis  
• Dennie -Morgan infraorbital fold  
• Keratoconus  
• Anterior subcapsular cataracts  
• Orbital darkening  
• Facial pallor/erythema  
• Pi[INVESTIGATOR_80166]  
• Anterior neck folds  
• Itch when sweating  
• Intolerance to wool and lipid solvents  
• Perifollicular accentuation  
• Food intolerance  
• Course influenced by [CONTACT_222224]/emotional factors  
• White dermographism/delayed blanch  
 
Source:  Hanifin , 1980.   
Tapi[INVESTIGATOR_222143].: DMVT -505-3101 , Amendment 3 
Dermavant Sciences , Inc.  Clinical Study Protocol  
Confidential  Page | 79 Appendix 2. Fitzpatrick Skin Type Scale   
 
Skin Type  Sunburn Te ndency  Suntan Tendency  
Type I  Always burns easily  Never tan  
Type II  Always burns easily  Tans slightly  
Type III  Burns moderately  Tans gradually  
Type IV  Burns minimally  Tans moderately  
Type V  Rarely burns  Tans profusely  
Type VI  Never burns  Tans profusely  
 
  
Tapi[INVESTIGATOR_222143].: DMVT -505-3101 , Amendment 3 
Dermavant Sciences , Inc.  Clinical Study Protocol  
Confidential  Page | 80 Appendix 3. Validated Investigator Global Assessment Scale for Atopic Dermatitis   
Instructions:  
The IGA score is selected using the descriptors below that best describe the overall appearance of the lesions 
(excluding lesions on the scalp) at a given time point. It is not necessary that all characteristics under 
Morphological Description be present.  
 
 
Score  Morphological Description  
0 – Clear  No inflammatory signs of atopic dermatitis (no erythema, no 
induration/papulation, no lichenification, no oozing/crusting). Post -inflammatory 
hyperpi[INVESTIGATOR_22758]/or hypopi[INVESTIGATOR_22765].  
1 – Almost  clear  Barely perceptible erythema, barely perceptible induration/papulation, and/or 
minimal lichenification. No oozing or crusting.  
2 – Mild  Slight but definite erythema (pi[INVESTIGATOR_8745]), slight but definite induration/papulation, and/or 
slight but definite lichen ification. No oozing or crusting.  
3 – Moderate  Clearly perceptible erythema (dull red), clearly perceptible induration/papulation, 
and/or clearly perceptible lichenification. Oozing and crusting may be present.  
4 – Severe  Marked erythema (deep or bright red), marked induration/papulation, and/or 
marked lichenification. Disease is widespread in extent. Oozing or crusting may be 
present.  
Notes:  
1. In indeterminate cases, please use extent to differentiate between scores.  
For example:  
Patient with marked erythema (deep or bright red), marked papulation and/or marked lichenification that is 
limited in extent, will be considered “3 – Moderate” . 
2. Excoriations should not be considered when assessing disease severity.  
 
Copyright ©2017 Eli Lilly and Company – Used with the permission of Eli Lilly and Company under a Creative Commons  
Attribution -No Derivatives 4.0 International License – https://creativecommons.org/licenses/by -nd/4.0/.  
  
Tapi[INVESTIGATOR_222143].: DMVT -505-3101 , Amendment 3 
Dermavant Sciences , Inc.  Clinical Study Protocol  
Confidential  Page | 82 Calculation of EASI score (scalp excluded)  
Four anatomic sites – head, upper extremitie s, trunk, and lower extremities – are assessed for erythema,  
edema/papulation , excoriation and lichenification as seen on the day of the examination.  The severity of each 
sign is assessed using a 4 -point scale , half points may be used (e.g. 0.5, 1.5, 2.5) : 
0 = None (Absent)  
1 = Mild  
2 = Moderate  
3 = Severe  
The area affected by [CONTACT_222225] a given anatomic site is estimated as a percentage of the total area of that 
anatomic site, based on the %BSA calculation, and assigned a numerical value according to the degree of AD 
involvement . For the purpose of assigning a numerical value for each anatomic site, %BSA ranges will be 
used as follows:  
0 = no (0%) involvement  
1 = > 0% to < 9.50% involvement  
2 = ≥ 9.50% to < 29.50% involvement  
3 = ≥ 29.50% to < 49.50% involvement  
4 = ≥ 49.50% to < 69.50% involvement  
5 = ≥ 69.50% to < 89.50% involvement   
6 = ≥ 89.50% to 100% involvement  
The EASI score will be calculated in the CRF based on the subject’s age, the rating scores for each region, 
and the number of handprints  involved for each region.  
  
Tapi[INVESTIGATOR_222143].: DMVT -505-3101 , Amendment 3 
Dermavant Sciences , Inc.  Clinical Study Protocol  
Confidential  Page | 86   
 

Tapi[INVESTIGATOR_222143].: DMVT -505-3101 , Amendment 3 
Dermavant Sciences , Inc.  Clinical Study Protocol  
Confidential  Page | 87   
 

Tapi[INVESTIGATOR_222143].: DMVT -505-3101 , Amendment 3 
Dermavant Sciences , Inc.  Clinical Study Protocol  
Confidential  Page | 88   

Tapi[INVESTIGATOR_222143].: DMVT -505-3101 , Amendment 3 
Dermavant Sciences , Inc.  Clinical Study Protocol  
Confidential  Page | 89 

Tapi[INVESTIGATOR_222143].: DMVT -505-3101 , Amendment 3 
Dermavant Sciences , Inc.  Clinical Study Protocol  
Confidential  Page | 91 

Tapi[INVESTIGATOR_222143].: DMVT -505-3101 , Amendment 3 
Dermavant Sciences , Inc.  Clinical Study Protocol  
Confidential  Page | 94 Appendix 11.  Peak Pruritus -Numeric Rating Scale   
 
The P P-NRS is a scale used to quickly assess itch/pruritus severity over a 24 -hour period  which will be used 
daily to assess peak pruritus .   
For subjects ages 2 to < 12 years, the PP -NRS will be completed by [CONTACT_18629] .  For subjects  ages > [ADDRESS_267034].    
 
PP-NRS  
On a scale of 0 to 10, with 0 being  ’no itch‘ and 10 being ’worst itch imaginable‘, how would you rate your 
itch at the worst moment during the previous 24 hours?  
 
 
 
PP-NRS © 2019 Regeneron Pharmaceuticals, Inc. and SAR&D. All rights reserved. Used with permission of 
Regeneron Pharmaceutic als, Inc. and SAR&D  
 
 
 
 
  

Tapi[INVESTIGATOR_222143].: DMVT -505-3101 , Amendment 3 
Dermavant Sciences , Inc.  Clinical Study Protocol  
Confidential  Page | 95   
 

Tapi[INVESTIGATOR_222143].: DMVT -505-3101 , Amendment 3 
Dermavant Sciences , Inc.  Clinical Study Protocol  
Confidential  Page | 98   

Tapi[INVESTIGATOR_222143].: DMVT -505-3101 , Amendment 3 
Dermavant Sciences , Inc.  Clinical Study Protocol  
Confidential  Page | 102 

Tapi[INVESTIGATOR_222143].: DMVT -505-3101 , Amendment 3 
Dermavant Sciences , Inc.  Clinical Study Protocol  
Confidential  Page | 103 Appendix  15. Investigator -Assessed Loca l Tolerability Scale   
At each specified study visit, the Investigator (or qualified evaluator) will assess the presence and overall 
degree of irritation at the application sites, according to the 5 -point LTS below.  The score will ideally 
represent an “average” across all application sites.  To the fullest extent possible, the same Investigator (or 
designated evaluator) will perform all tolerability assessments for an individual su bject throughout the study.  
If the subject is applying study drug to “sensitive areas”, a separate LTS will be used to assess the degree of 
irritation for each of these areas where study drug is applied.  The sensitive areas that will be assessed are 
face,  neck, skin folds, axilla, inframammary, anal crux, and genitalia.    
 
Investigator Local Tolerability Scale – Dryness, Erythema, and Peeling  
Score  Severity  Description  
0 No irritation  No evidence of local irritation/intolerance  
1 Mild  Minimal erythema and/or edema, slight glazed appearance  
2 Moderate  Definite erythema and/or edema with peeling and/or cracking but does not 
require treatment modification  
3 Severe  Erythema, edema glazing with fissures, few vesicles or papules  
4 Very Severe  Strong reaction spreading beyond the treated area, bullous reaction, 
erosions  
 
  
Tapi[INVESTIGATOR_222143].: DMVT -505-3101 , Amendment 3 
Dermavant Sciences , Inc.  Clinical Study Protocol  
Confidential  Page | [ADDRESS_267035] (or Caregiver) -Assessed Local Tolerability Scale   
At each specified study visit, th e subject or caregiver will separately assess the presence and degree of 
burning/stinging and itching at the application sites, each according to a [ADDRESS_267036] or 
caregiver will not score each sensitive area individually but provide one overa ll score that will ideally 
represent an “average” across all application sites.  For subjects ages < 12 years, the LTS will be completed 
by [CONTACT_18629].  For subjects ages > [ADDRESS_267037] (Or Caregiver) Loca l Tolerability Scale – Burning /Stinging  
Score  Severity  Description  
0 None  Normal, no discomfort  
1 Slight  An awareness, but no discomfort and no intervention required  
2 Mild  A noticeable discomfort that causes intermittent awareness  
3 Moderate  A noticeable discomfort that causes intermittent awareness and interferes 
occasionally with normal daily activities  
4 Strong/Severe  A definite continuous discomfort that interferes with normal daily activities  
 
Subject (Or Caregiver) Local Tolerability Scale – Itching 
Score  Severity  Description  
0 None  Normal, no discomfort  
1 Slight  An awareness, but no discomfort and no intervention required  
2 Mild  A noticeable discomfort that causes intermittent awareness  
3 Moderate  A noticeable discomfort that causes intermittent awareness and interferes 
occasionally with normal daily activities  
4 Strong/Severe  A definite continuous discomfort that interferes with normal daily activities  
 
  
Tapi[INVESTIGATOR_222143].: DMVT -505-3101 , Amendment 3 
Dermavant Sciences , Inc.  Clinical Study Protocol  
Confidential  Page | 105 
